



(86) Date de dépôt PCT/PCT Filing Date: 2008/10/07
(87) Date publication PCT/PCT Publication Date: 2009/04/09
(45) Date de délivrance/Issue Date: 2016/05/17
(85) Entrée phase nationale/National Entry: 2010/03/30
(86) N° demande PCT/PCT Application No.: US 2008/079090
(87) N° publication PCT/PCT Publication No.: 2009/046464
(30) Priorité/Priority: 2007/10/05 (US11/867,919)

(51) Cl.Int./Int.Cl. *C12N 15/12* (2006.01),
A61K 38/18 (2006.01), *A61K 48/00* (2006.01),
C07K 14/51 (2006.01), *C12N 15/861* (2006.01)
(72) Inventeur/Inventor:
FISCHER, LAURENT BERNARD, FR
(73) Propriétaire/Owner:
MERIAL, INC., US
(74) Agent: SMART & BIGGAR

(54) Titre : THERAPIE GENIQUE DE CARTILAGE ARTICULAIRE UTILISANT UN VECTEUR RECOMBINE CODANT
POUR BMP-7
(54) Title: ARTICULAR CARTILAGE GENE THERAPY WITH RECOMBINANT VECTOR ENCODING BMP-7

(57) **Abrégé/Abstract:**

The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intraarticular administration of the recombinant vectors and pharmaceutical compositions of the invention.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/046464 A1

(51) International Patent Classification:

C12N 15/12 (2006.01) *C07K 14/51* (2006.01)
C12N 15/861 (2006.01) *A61K 38/18* (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2008/079090

(22) International Filing Date: 7 October 2008 (07.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11/867,919 5 October 2007 (05.10.2007) US

(71) Applicant (for all designated States except US): **MERIAL LIMITED** [US/US]; 3239 Satellite Blvd., Duluth, GA 30096 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **FISCHER, Laurent, Bernard** [FR/FR]; 17, Chemin Vert 69110, Sainte Foy Les Lyon (FR).

(74) Agent: **JARECKI-BLACK, Judy.**; Merial Limited, 3239 Satellite Blvd., Duluth, GA 30096 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- with information concerning request for restoration of the right of priority in respect of one or more priority claims; the decision of the receiving Office regarding the request for restoration is pending and will be published separately once available

(54) Title: ARTICULAR CARTILAGE GENE THERAPY WITH RECOMBINANT VECTOR ENCODING BMP-7

(57) Abstract: The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intraarticular administration of the recombinant vectors and pharmaceutical compositions of the invention.



WO 2009/046464 A1

51440-134

TITLE OF THE INVENTION

ARTICULAR CARTILAGE GENE THERAPY WITH RECOMBINANT VECTOR
ENCODING BMP-7

5 This application claims priority to US Patent Application 11/867,919
filed October 5, 2007, and published as US 2009-0093427 A1.

 All documents cited or referenced herein ("herein cited documents"), and all
documents cited or referenced in herein cited documents, together with any manufacturer's
instructions, descriptions, product specifications, and product sheets for any products
10 mentioned herein may be employed in the practice of the invention.

FIELD OF THE INVENTION

 The present invention relates to recombinant vectors, to pharmaceutical compositions
comprising such recombinant vectors, and to methods to ensure cartilage repair, and/or slow
15 down osteoarthritis evolution and/or reverse osteoarthritis evolution in vertebrates. The
invention also relates to vectors capable of expressing, in a host, a bioactive polypeptide
belonging to the Osteogenic Protein-1 / Bone Morphogenetic Protein-7 (OP-1 / BMP-7)
family of proteins. The invention also relates to intra-articular gene therapy with such
vectors.

20 **BACKGROUND OF THE INVENTION**

 Osteoarthritis (OA) is a chronic degenerative disease of the joints of vertebrates. Pain
is the predominant presenting symptom of OA. Vertebrates with OA, including humans,
mammalian animals, particularly athlectic-horses, dogs and cats, have pain that typically
worsens with weight bearing and activity and improves with rest, as well as morning stiffness
25 and gelling of the involved joints after periods of inactivity. Such signs and symptoms of the
disease often culminate in reductions in quality of life. The disease is more frequent in a
subset of the joints of the body, particularly the hips, knees, shoulders, elbows, intercarpus
and intertarsus joints.

 Diarthrodial joints are organs of locomotion of vertebrates. They achieve almost
30 frictionless motion, thanks to the unique biological, chemical and mechanical properties of
the articular cartilage that covers the articulating surfaces of the long bones. Articulation
occurs within a synovial cavity, or joint space, whose intimal surface is lined by synovium
and within which there normally exists a small volume of lubricating synovial fluid. Certain
joints, such as the knee have additional, nonarticular cartilaginous structures, known as

51440-134

menisci. The synovium lines a fibrous capsule, beyond which lies the musculature and ligamentous extra-articular supporting structures of the joint.

Current OA impact in humans is tremendous and rivals that of ischemic heart disease in many regards. As baby boomers reach late adulthood and the obesity epidemic rages on,
 5 OA will assume an even greater impact on society. In younger populations, athletes participating in contact sports or activities, such as excessive running, are also at high risk for the development of OA.

In veterinary medicine, OA is very common in horses and dogs but is also recognised in cats, albeit at a lower extent.

10 In the equine industry, lameness due to joint injury and disease is the most prevalent cause of diminished athletic function and wastage in racing horses. Together, joint injury and joint disease represent a large majority of the equine clinician's caseload. Equine OA can originate from various causes, with trauma and concomitant synovitis being the most common causes of lack of performance in horses. Often OA stems from overuse or
 15 conformational inadequacies that predispose an athletic horse to inappropriate biomechanical forces on cartilage.

In the dog, OA is one of the most common chronic musculoskeletal diseases and causes of lameness. It is frequently secondary to congenital or acquired musculoskeletal disorders. Several arthropathies can affect the young dog and lead to secondary OA,
 20 including joint dysplasia, osteochondrosis dissecans, un-united anconeal process and patellar luxation. In addition to developmental abnormalities, there are many acquired musculoskeletal disorders associated to cartilage deterioration. In some cases, trauma may directly induce an isolated chondral lesion that can be the onset of an extended and progressive degenerative lesion. After ligamentous lesions, cartilage injuries may appear
 25 some weeks later as a consequence of joint instability. Intra-articular fractures are often complicated by secondary cartilage degradation, as a consequence of incomplete fracture reduction. Joint luxation or luxation reduction are commonly complicated by ligament and capsule damage and/or cartilage lesions. Obesity is more and more understood as an important risk factor for OA in dogs as it is in human medicine.

30 OA is characterized by biochemical and enzymatic changes, cartilage fragmentation and loss, osteophytes formation and bony sclerosis. Although the causes of OA are not completely understood, biochemical stresses affecting the articular cartilage and subchondral bone, biochemical changes in the articular cartilage and synovial membrane, and genetic factors are all important in OA pathogenesis.

Most often, the inflammatory process begins in the synovium, cartilage, joint capsule or subchondral bone and quickly initiates a cascade of inflammatory mediators from the primary tissue of insult. This often causes a “domino effect” of the inflammatory process into the secondary tissues that in turn release inflammatory mediators.

5 Regardless of the species, the molecular and cellular inflammatory events associated to OA involve the release of metabolites of arachidonic acid in the cell membrane. This in turn initiates pain by means of prostaglandins. Degradation of hyaluronic acid in the joint fluid results from chemoattractants and by-products of the inflammatory pathway, lysosomal enzymes, and non-lysosomal enzymes elaborated by injured synoviocytes, and oxygen-derived
10 free radicals from neutrophils and macrophages.

 Degeneration of the articular cartilage is considered the sine qua non of OA. Gross findings include fibrillation, erosion and wear lines in the articular cartilage. Histological characteristics include superficial fibrillation, which can progress to form vertical clefts down to subchondral bone. Often the proteoglycan content of the articular cartilage is reduced
15 along with the breakdown of collagen. This results in increased water uptake in cartilage leading to a biomechanically “softer” cartilage surface. These findings can also be accompanied by chondrocyte necrosis and eventual full-thickness loss of articular cartilage. Pathological changes may occur in associated structures as well. Subchondral bone sclerosis commonly accompanies cartilage degeneration, and the demarcation between hyaline and
20 calcified articular cartilage becomes penetrated with blood vessels. Chronic progression of these changes leads to formation of periarticular lipping at the joint margins due to progressive overgrowth of cartilage and subchondral bone along the borders of articulations. The synovial lining and fibrous layer of the joint capsule are altered in OA. The synovium becomes congested, discoloured, and thickened. Histologically, synoviocytes appear
25 hypertrophic, and lymphoplasmacytic cells and macrophages may be present in the subintimal stroma of the synovial tissues.

 Numerous medical treatments have been used extensively in the treatment of OA. To date, most treatments have been directed towards lowering and then maintaining a decreased degree of inflammation within damaged joints. Relatively little attention has been focused on
30 therapeutic agents that actually protect the joint tissues and which have been classified by the International League Against Rheumatism (ILAR) guidelines as “disease modifying” OA drugs (DMOADs). Therapy with this class of drugs should, in theory, prevent, retard or reverse morphologic cartilaginous lesions of OA.

Non steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids have been the primary mode of anti-inflammatory therapy. Although non steroidal anti-inflammatory drugs often provide symptomatic relief, little protection and regeneration is afforded to the articular cartilage, nor do the drugs modify the underlying disease process. Many NSAIDs are also associated to significant incidence of undesirable side effects, making their long-term use problematic. Corticosteroids also are commonly used to treat OA and are powerful mediators of reducing pain and inflammation. However, untoward effects on articular cartilage, including impaired chondrocyte activity, decreased glycosaminoglycans and proteoglycans content and decreased cartilage elasticity are reported.

In veterinary practice, aforementioned therapies are sometimes combined for an additive, if not a synergistic, response to joint injury. Often NSAIDs or steroids are combined with hyaluronic acid treatments to improve the viscoelasticity of the joint fluid and boundary lubrication of the intra-articular soft tissues. Patients are also frequently placed on parenteral as well as oral polysulphated glycosaminoglycans (PSGAGs) to sustain or promote chondrocyte metabolic activity and inhibit the detrimental effects of cytokines or prostaglandins on cartilage. While no well-controlled clinical studies have evaluated this “shotgun” approach, each drug has beneficial effects and no adverse effects have been reported to date from using these many different modes of therapy.

Therapeutic intervention in OA is further hindered, in part, by the inability to target therapeutic agents directly into the joints. Traditional oral, intravenous and intramuscular routes are relatively ineffective, because small molecules enter the joint space by passive diffusion and large molecules (such as proteins) are excluded from the joint space. Although intra-articular administration bypasses these limitations, the half-life of most agents directly administered into the joint space remains short and frequent intra-articular injections are needed to sustain biologic activities for prolonged treatments of chronic diseases.

In conclusion, as to date, no therapeutic agent has effectively, and without side effects, eliminated the progression of OA. There is therefore a crying medical need for truly innovative DMOADs strategies for both human and veterinary applications.

Recently, Osteogenic Protein 1 (OP-1), alias Bone Morphogenetic Protein 7 (BMP-7), previously known to promote bone formation and healing, has been demonstrated to play a significant role in articular cartilage regeneration and repair, potentially acting as a DMOADs. Various studies have shown that, when exposed to BMP-7, mesenchymal cells have the potential to differentiate into cells that behave phenotypically as chondrocytes. These cells, both in vitro and in vivo, produce matrix with type II collagen and proteoglycans

specific for articular cartilage. This finding has been confirmed in various animal models including a canine large full-thickness osteochondral defect model. The repair tissue obtained has been observed to have hyaline-like appearance and to be maintained over long-term animal studies.

5 However, the use of BMP-7 for OA therapy is not without limitations and potential complications. Recombinant purified BMP-7 protein in solution is not providing the expected therapeutic benefit when merely injected into a joint because of rapid elimination from the joint space through the synovial vascularisation. Short half-life of the protein within the articulation requires the recombinant BMP-7 protein to be included into an appropriate
10 biological carrier material to ensure slow release and sustained local concentration. The biological carrier further secures the implant stability and physical network for cellular and vascular colonisation leading to cartilage formation. The high concentrations of recombinant protein to be included in the biological carrier (e.g., 340µg of OP-1 implant administered twice by intra-articular injection one week apart in a sheep post traumatic experimental OA
15 model (Hurtig MB *et al.*, Proceedings Combined Orthopaedic Research Society, 070, October 2004), 350µg of BMP-7 in bovine-derived type-I collagen device to repair an articular cartilage defect in a canidae surgically induced full thickness osteochondral defect (Cook S.D. *et al.*, J. Bone Joint Surgery, 2003, 85(3): 116-123)). In practical terms, the cost and the complexity of complexing large amounts of purified protein with an appropriate
20 biological carrier makes the procedure non economically viable in veterinary medicine. Further, from a safety standpoint, the use of large quantities of a powerful osteoinductive protein raises the possibility of ectopic bone formation, particularly if the site of implantation is not well contained.

 Gene transfer is an attractive strategy to circumvent limitations facing purified
25 recombinant proteins. As gene can be delivered and expressed locally within joints, highest concentrations of therapeutic proteins can be produced in situ within the joint, thereby reducing the likelihood of unwanted side effects to a minimal as non-target organs will receive less exposure. The synovium is an attractive target tissue for gene expression because of its large surface and its direct contact with the joint space. Although the articular cartilage
30 is another available target tissue within the joint, lack of vector penetration through the extracellular matrix is considered an important technical limitation.

 Two methods of transferring genes to joints can be considered: ex vivo and in vivo gene transfers.

Ex vivo gene transfer refers to the harvest of cells, their in vitro genetic modification and their subsequent back grafting into the joint. Indeed, accelerated cartilage repair has been demonstrated following transplantation of chondrocytes transduced ex vivo with an Ad5 expressing BMP-7 in an equine cartilage defect model. As this technology allows genetic
5 manipulations outside of the body it is associated to an increased safety profile. However, the approach is facing multiple practical issues as it is time and resources consuming for harvesting, manipulating and re-implanting cells. Further, the longevity of the recombinant protein expression in the chondrocytes transplants remains a limiting factor and requires either very high initial doses or repeat treatments. Clinical applicability of such a strategy is
10 complex and cumbersome, dramatically limiting commercialization potential in veterinary medicine.

In contrast, in vivo gene transfer refers to the direct targeting of synoviocytes or chondrocytes in the joint itself, which is achievable at the clinical level using appropriate vectors. However, this later strategy is also restricted by significant limitations, the exact
15 nature of which depends on the specific vector system that is considered.

Adenoviruses possess many advantages as gene therapy vectors, including the ease to generate high titers of recombinant viruses, the wide range of cell types, including non dividing cells, that are susceptible to efficient transduction by such viruses. The so-called first generation recombinant human adenovirus serotype 5 (Ad5) is based on the deletion of the
20 E1 and potentially the E3 regions of the viral genome. These modifications provide loci for transgene insertion but also result in the prevention of late genes activation, upon which viral replication in target species depends. Such advantages have led to the widespread application of Ad5 vectors both in preclinical and clinical studies. However, the death of a human patient exposed to very large Ad5 doses in 1999 has tarnished the safety record of adenovirus
25 vectors. As of today, the safety of Ad5 vectors administered systemically is considered questionable by many.

However, significant limitations or uncertainties face the utility of this vector for clinical use in joints. The trigger of an anti Ad5 immune response may interfere with the transgene delivery and long-term expression but also may cause pathology, usually
30 inflammatory. Immune and inflammatory interferences have indeed been noticed with recombinant Ad5 delivered intra-articularly in mice, rats, rabbits or horses. Although batch to batch variations and purity may be involved, the amount of viral particles injected intra-articularly appears a key aspect driving Ad5 associated inflammation for intra-articular gene therapy. As the efficacy of the Ad5 vector to trigger expression of the transgene within the

joint can be proportional to the injected dose, the selection of the appropriate balance between efficacy and safety for articular gene therapy remains a technical challenge.

The definition of an Ad5 dosage compatible with long-term expression of the recombinant protein within the joint is not clear from existing literature. Indeed, when an Ad5
5 expressing IGF1 was injected into an equine fetlock joint, significant expression of IGF1 was detectable in the synovial fluid only for those horses receiving very high doses (50×10^{10} viral particles (VP)) (Goodrich LR *et al.*, Gene Therapy, 2006, 13: 1253-1262). No significant expression was noticed with lower doses. This high Ad5 dosage is associated to an increase in white blood cells (WBC) in the synovial fluid, demonstrating a significant local
10 inflammation. Under these conditions, expression of IGF1 peaked at day 4 post injection and declined thereafter. Temporal declines in transgene expression over a period of 2-4 weeks have been observed in other studies using Ad5 as a delivery vector. Although the transient elevation could positively impact cartilage healing in the first 4 weeks and possibly longer, the need for vectors that express proteins for months rather than weeks is considered
15 preferable by many authors in the literature. Indeed, most investigators seeking prolonged gene expression are currently re-orienting their efforts to alternative existing vector systems, such as adeno-associated viruses (AAVs) or lentiviruses.

Prior reports of *in vivo* usage of recombinant BMP-7 protein for cartilage repair indicated that very high amounts of recombinant protein were required (e.g., 340 μ g of OP-1
20 implant administered twice by intra-articular injection one week apart in a sheep post traumatic experimental OA model (Hurtig MB *et al.*, Proceedings Combined Orthopaedic Research Society, 070, October 2004), 350 μ g of BMP-7 in bovine-derived type-I collagen device to repair an articular cartilage defect in a canidae surgically induced full thickness osteochondral defect (Cook S.D. *et al.*, J. Bone Joint Surgery, 2003, 85(3): 116-123)). These
25 amounts are significantly higher than the peak amounts (73 ng/ml) reported in studies using the aforementioned Ad5 IGF1 (Goodrich LR *et al.*, Gene Therapy, 2006, 13: 1253-1262). As a consequence, prior experience with Ad5 vectors for joint gene therapy do not support the use of an Ad5 BMP-7 vector to reach therapeutical concentrations *in vivo*.

Of further relevance, prior use of high doses of Ad5 BMP7 for *in vivo* bone formation
30 in immunocompetent rats was unsuccessful whereas the exact same recombinant virus was able to trigger significant bone formation in immunocompromized rats (Li JZ *et al.*, Gene Therapy, 2003, 10: 1735-1743). This example further illustrates the complexity of the prediction of efficacy of an Ad5 BMP7 *in vivo*.

The technical problem to be addressed is to ensure articular cartilage repair and thereby slow down and potentially reverse osteoarthritis disease evolution in mammals.

Articular cartilage covers the articulating surfaces of the portions of bones in joints. The cartilage allows movement in joints without direct bone-to-bone contact, thereby preventing wearing down and damage of opposing bone surfaces. Articular cartilage has no tendency to ossification. The cartilage surface appears smooth and pearly macroscopically, and is finely granular under high power magnification. Such cartilage is referred to as hyaline cartilage, as opposed to fibrocartilage and elastic cartilage. Articular cartilage appears to derive its nutriment partly from the vessels of the neighboring synovial membrane, partly from those of the bone that it covers. Articular cartilage is associated with the presence of Type II and Type IX collagen and various well-characterized proteoglycans, and with the absence of Type X collagen, which is associated with endochondral bone formation. For a detailed description of articular cartilage micro-structure, see, for example, Aydelotte and Kuettner, *Conn. Tiss. Res.* 18:205 (1988); Zanetti *et al.*, *J. Cell Biol.* 101:53 (1985); and Poole *et al.*, *J. Anat.* 138:13 (1984).

Other types of permanent cartilage in adult mammals include fibrocartilage and elastic cartilage. In fibrocartilage, the mucopolysaccharide network is interlaced with prominent collagen bundles and the chondrocytes are more widely scattered than in hyaline cartilage. Interarticular fibrocartilages are found in those joints which are most exposed to violent concussion and subject to frequent movement, e.g., the meniscus of the knee. Examples of such joints include the temporo-mandibular, sterno-clavicular, acromio-clavicular joints. Elastic cartilage contains collagen fibers that are histologically similar to elastin fibers. Such cartilage is found in the human body in the auricle of the external ear, the Eustachian tubes, the cornicula laryngis, and the epiglottis.

Bone Morphogenetic Protein-7 (BMP-7, or Osteogenic Protein-1, OP-1) is a member of the Transforming Growth Factor- β (TGF- β) superfamily. BMP-7 binds to activin receptors types I and II, but not to TGF- β receptors type I, II and III. Monomeric BMP-7 has a molecular weight of 17 to 19 kDa and was identified by its ability to induce ectopic bone formation. BMP-7 polypeptide is secreted as a homodimer with an apparent molecular weight of approximately 35-36 kDa.

However, because BMP-7 has a short half live *in vivo* (approximately 30 min), maintenance of a sustained level of exogenous protein in the circulation following injection of the purified protein requires multiple short-interval administrations, creating a very

significant practical challenge. The cost of such a multi-injection therapy is too high to be applicable in veterinary medicine. Although gene delivery has been successfully promoted as an alternative to protein therapy for various diseases treatment, it's applicability for osteoarthritis prevention and/or treatment through BMP-7 polypeptide expression *in vivo* has not been proposed previously, and its potential effectiveness remains uncertain. Indeed, the low molecular weight of the BMP-7 homodimer (i.e., approximately 35 kDa) would theoretically allow for rapid glomerular filtration. Whether or not levels of BMP-7 expressed *in vivo* could reach therapeutically effective plasma concentrations cannot be predicted or determined from the existing literature. To further complicate the evaluation of *in vivo*-expressed BMP proteins, results can be variable depending on the immune status of the treated animal, with significant differences between immune competent and incompetent animals. Thus, when considered collectively as a whole, the literature does not teach whether levels of BMP-7 expressed *in vivo* could reach plasma concentrations that would be therapeutically useful.

Citation or identification of any document in this application does not constitute an admission that such document is available as prior art to the present invention.

SUMMARY OF THE INVENTION

The present invention is directed to methods of prevention and treatment of mammalian subjects who are suffering from, or who are at risk of, osteoarthritis (OA), and to recombinant vectors and pharmaceutical compositions for use in such methods. The methods, vectors and compositions of the invention may be useful for reducing, preventing, inhibiting, delaying, or alleviating the progressive loss of articular function which characterizes osteoarthritis. Subjects for which the methods, recombinant vectors, and compositions of the present invention are useful include, but are not limited to, subjects already afflicted with OA, as well as any subject reasonably expected to suffer from a progressive loss of articular function associated with OA. Whether a particular subject is at risk of OA and/or whether a subject may benefit from the methods and/or compositions of the present invention, is a determination that can be routinely made by one of ordinary skill in the relevant medical or veterinary art. Subjects at risk of OA are notably athletic mammals, like athletes participating in contact sports or activities, such as excessive running, racing horses, racing dogs, dogs of the army and/or police forces, obese mammals (i.e. humans and pets, such as dogs and cats), mammals having congenital or acquired musculoskeletal disorders, old mammals...

51440-134

In an embodiment, the present invention relates to the use of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle and recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter for treating a non-human mammalian
5 subject suffering from osteoarthritis, wherein the composition is for intra-articular administration to said non-human mammalian subject, wherein the BMP-7 polypeptide is expressed in vivo in the non-human mammalian subject, and wherein the BMP-7 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, and SEQ ID NO:28.

51440-134

In another embodiment the present invention relates to a vector which may contain and express a pre-pro BMP-7 gene, a proBMP-7 gene or a mature BMP-7 gene in a host. The BMP-7 gene encoding the pre-proBMP-7 polypeptide, the proBMP-7 polypeptide or the mature BMP-7 polypeptide may originate from a mammal. In a preferred embodiment, the expression vector may comprise a polynucleotide that encodes a canine pre-proBMP-7, a canine pro-BMP-7 or a canine mature BMP-7 polypeptide. In another preferred embodiment, the expression vector may comprise a polynucleotide that encodes a feline pre-proBMP-7, a feline pro-BMP-7 or a feline mature BMP-7 polypeptide. In another preferred embodiment, the expression vector may comprise a polynucleotide that encodes an equine pre-proBMP-7, an equine pro-BMP-7 or an equine BMP-7 polypeptide. In another preferred embodiment, the expression vector may comprise a polynucleotide that encodes a human pre-proBMP-7, a human pro-BMP-7 or a human mature BMP-7 polypeptide. The polynucleotide encoding the BMP-7 polypeptide may be operatively linked to a promoter and optionally to an enhancer.

In an advantageous embodiment, the invention relates to a vector containing and expressing the canine proBMP-7 polypeptide, wherein the canine proBMP-7 polypeptide is deleted of the "pre" peptide at the N-terminus, and wherein a peptide signal sequence from a different origin is fused to the canine proBMP-7 polypeptide. In another advantageous embodiment, the invention relates to a vector containing and expressing the feline proBMP-7 polypeptide, wherein the feline proBMP-7 polypeptide is deleted of the "pre" peptide at the N-terminus, and wherein a peptide signal sequence from a different origin is fused to the feline proBMP-7 polypeptide. In another advantageous embodiment, the invention relates to a vector containing and expressing the equine proBMP-7 polypeptide, wherein the equine proBMP-7 polypeptide is deleted of the "pre" peptide at the N-terminus, and wherein a peptide signal sequence from a different origin is fused to the equine proBMP-7 polypeptide. In another advantageous embodiment, the invention relates to a vector containing and expressing the human proBMP-7 polypeptide, wherein the human proBMP-7 polypeptide is deleted of the "pre" peptide at the N-terminus, and wherein a peptide signal sequence from a different origin is fused to the human proBMP-7 polypeptide. Advantageously, the peptide signal sequence may be the insulin-like growth factor 1 (IGF-1) or the tissue plasminogen activator (tPA) peptide signal sequence. In another embodiment, the expression vector may comprise a polynucleotide that encodes a canine mature BMP-7 polypeptide wherein said polypeptide is fused with a peptide signal sequence from BMP-7, IGF-1 or tPA. In another embodiment, the expression vector may comprise a polynucleotide that encodes a feline mature BMP-7 polypeptide wherein said polypeptide is fused with a peptide signal sequence

from BMP-7, IGF-1 or tPA. In another embodiment, the expression vector may comprise a polynucleotide that encodes an equine mature BMP-7 polypeptide wherein said polypeptide is fused with a peptide signal sequence from BMP-7, IGF-1 or tPA. In another embodiment, the expression vector may comprise a polynucleotide that encodes a human mature BMP-7 polypeptide wherein said polypeptide is fused with a peptide signal sequence from BMP-7, IGF-1 or tPA.

In another embodiment the invention relates to a pharmaceutical composition comprising a vector expressing a pre-proBMP-7 polypeptide, a proBMP-7 polypeptide or a mature BMP-7 polypeptide and a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle. In a particular embodiment, the pharmaceutical composition may comprise a substance to improve the efficacy of transfection or transduction of the vector into the host cells.

In yet another embodiment the invention relates to a method for delivering the BMP-7 polypeptide to a mammal which may comprise injecting intra-articularly into the synovial fluid a vector capable of expressing, *in vivo*, a pre-proBMP-7 polypeptide, a proBMP-7 polypeptide or a mature BMP-7 polypeptide. In an advantageous embodiment, the mammalian host may be a human, a canidae, an equidae or a felidae, notably man, woman, child, dog, bitch, puppy, horse, mare, foal or cat, kitten. The invention relates to the use of such a vector to prevent and/or treat a mammal for OA.

It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

These and other embodiments are described in, or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description, given by way of example but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, in which:

FIG. 1 provides macroscopic data of macroscopic lesions shown on treated and non-treated knees of sheep at necropsy, 90 days after osteoarthritis artificially created by impact.

FIG. 2 provide histologic pictures of the left and right knee of one of the animals of Group 1 of the Example 8 (Y13).

FIG. 3 provides cartilage preservation after injury expressed in square-millimeter of cartilage surface roughening as measured by India ink retention for BMP-7 treated joints and contralateral non-treated joints of animals of group 1 and for non-treated animals of group 2.

FIG. 4 provides quantitative histological observations using OARSI scoring with assigning a grade to the depth of cartilage erosion and a stage to the India ink stained area (expressed in square-millimeter of cartilage surface roughening as measured by India ink retention) for BMP-7 treated joints and contralateral non-treated joints of animals of group 1 and for non-treated animals of group 2.

Also included as part of the present application is a sequence listing in which: SEQ ID NO: 1 is the nucleotide sequence of the canine pre-proBMP-7 polypeptide, SEQ ID NO: 2 is the codon-optimized nucleotide sequence of the canine pre-proBMP-7 polypeptide, SEQ ID NO: 3 is the amino acid sequence of the canine pre-proBMP-7 polypeptide, SEQ ID NO: 4 is the nucleotide sequence of the short signal peptide from tPA (23 amino acids), SEQ ID NO: 5 is the amino acid sequence of the short signal peptide from tPA (23 amino acids), SEQ ID NO: 6 is the nucleotide sequence of the long signal peptide from tPA (28 amino acids), SEQ ID NO: 7 is the amino acid sequence of the long signal peptide from tPA (28 amino acids), SEQ ID NO: 8 is the nucleotide sequence of the equine IGF-1 signal peptide, SEQ ID NO: 9 is the amino acid sequence of the equine IGF-1 signal peptide, SEQ ID NO: 10 is the nucleotide sequence of the equine pre-proBMP-7 polypeptide, SEQ ID NO: 11 is the nucleotide sequence of the canine IGF-1 signal peptide, SEQ ID NO: 12 is the amino acid sequence of the canine IGF-1 signal peptide, SEQ ID NO: 13 is the nucleotide sequence of the human pre-proBMP-7 polypeptide, SEQ ID NO: 14 is the codon-optimized nucleotide sequence of the human pre-proBMP-7 polypeptide, SEQ ID NO: 15 is the amino acid sequence of the human pre-proBMP-7 polypeptide, SEQ ID NO: 16 is the amino acid sequence of the equine pre-proBMP-7 polypeptide, SEQ ID NO: 17 is the nucleotide sequence of the feline pre-proBMP-7 polypeptide, SEQ ID NO: 18 is the codon-optimized nucleotide sequence of the feline pre-proBMP-7 polypeptide, and SEQ ID NO: 19 is the amino acid sequence of the feline pre-proBMP-7 polypeptide, SEQ ID NO: 20 is the nucleotide sequence of the PB1053 primer, SEQ ID NO: 21 is the nucleotide sequence of the PB1063 primer, SEQ ID NO: 22 is the nucleotide sequence of the PB1060 primer, SEQ ID NO: 23 is the nucleotide sequence of the PB1062 primer, SEQ ID NO: 24 is the nucleotide sequence of the PB1088 primer, SEQ ID NO: 25 is the nucleotide sequence of the PB1089

primer, SEQ ID NO: 26 is the nucleotide sequence of the PB1090 primer, SEQ ID NO: 27 is the nucleotide sequence of the murine pre-proBMP-7 polypeptide, SEQ ID NO: 28 is the amino acid sequence of the murine pre-proBMP-7 polypeptide, SEQ ID NO: 29 is the nucleotide sequence of the LF189 primer, SEQ ID NO: 30 is the nucleotide sequence of the LF190 primer, SEQ ID NO: 31 is the nucleotide sequence of the LF191 primer, SEQ ID NO: 32 is the nucleotide sequence of the LF192 primer, SEQ ID NO: 33 is the nucleotide sequence of the DNA linker, SEQ ID NO: 34 is the nucleotide sequence of the LF327 primer, SEQ ID NO: 35 is the nucleotide sequence of the LF324 primer, SEQ ID NO: 36 is the nucleotide sequence of the LF326 primer, SEQ ID NO: 37 is the nucleotide sequence of the LF325 primer, SEQ ID NO: 38 is the nucleotide sequence of the LF361 primer, SEQ ID NO: 39 is the nucleotide sequence of the LF334 primer, SEQ ID NO: 40 is the nucleotide sequence of the LF437 primer, SEQ ID NO: 41 is the nucleotide sequence of the LF172 primer, SEQ ID NO: 42 is the nucleotide sequence of the LF159 primer, SEQ ID NO: 43 is the nucleotide sequence of the LF377 primer, SEQ ID NO: 44 is the nucleotide sequence of the LF378 primer, SEQ ID NO: 45 is the nucleotide sequence of the SPH6Etr1 primer, SEQ ID NO: 46 is the nucleotide sequence of the SPH6Etr2 primer, SEQ ID NO: 47 is the nucleotide sequence of the SPH6Etr3 primer, SEQ ID NO: 48 is the nucleotide sequence of the SPH6Etr4 primer, SEQ ID NO: 49 is the nucleotide sequence of the SPH6Etr5 primer, SEQ ID NO: 50 is the nucleotide sequence of the SPH6Etr6 primer, SEQ ID NO: 51 is the nucleotide sequence of the SPH6Etr7 primer, SEQ ID NO: 52 is the nucleotide sequence of the SPH6Etr8 primer, SEQ ID NO: 53 is the nucleotide sequence of the LF394 primer, SEQ ID NO: 54 is the nucleotide sequence of the LF395 primer, SEQ ID NO: 55 is the nucleotide sequence of the LF397 primer, SEQ ID NO: 56 is the nucleotide sequence of the LF398 primer, SEQ ID NO: 57 is the nucleotide sequence of the M13R primer, SEQ ID NO: 58 is the nucleotide sequence of the LF409 primer, SEQ ID NO: 59 is the nucleotide sequence of the equine IL10 polypeptide, SEQ ID NO: 60 is the amino acid sequence of the equine IL10 polypeptide, SEQ ID NO: 61 is the nucleotide sequence of the canine IL10 polypeptide, SEQ ID NO: 62 is the amino acid sequence of the canine IL10 polypeptide, SEQ ID NO: 63 is the nucleotide sequence of the feline IL10 polypeptide, SEQ ID NO: 64 is the amino acid sequence of the feline IL10 polypeptide, SEQ ID NO: 65 is the nucleotide sequence of the human IL10 polypeptide, SEQ ID NO: 66 is the amino acid sequence of the human IL10 polypeptide, SEQ ID NO: 67 is the nucleotide sequence of the viral IL10 polypeptide, and SEQ ID NO: 68 is the amino acid sequence of the viral IL10 polypeptide.

DETAILED DESCRIPTION

The methods and compositions of the present invention can be used for therapeutic treatment of OA. The terms “therapy” or “therapeutic treatment”, as they relate to OA, and as they are used herein and in the field of veterinary medicine and human medicine, relate to treating mammals that are already suffering from, or are recovering from OA, or treatments aimed at slowing down and/or reversing morphologic cartilaginous lesion evolution in mammals diagnosed as having, or at being at risk of, OA. Whether a particular mammal suffers of OA, can readily be determined by one with ordinary skill in the relevant veterinary or medical art.

As used herein, a mammal is said to suffer from OA, if the mammal is reasonably expected to suffer a progressive loss of articular function associated with considerable loss of cartilage, the generation of wear particles, thickening of synovium and capsule disturbances in the subchondral bone and the growth of osteophytes at the margins of the joint.

The main result of OA in mammals includes, but is not limited to, lameness.

In humans, diagnosis of OA is primarily based on history and physical examination, but radiographic findings, including asymmetric joint space narrowing (JSN), subchondral sclerosis, osteophyte formation, subluxation, and distribution patterns of osteoarthritic changes are all helpful when diagnosis is uncertain. Structural morphological changes on X-rays are also considered the primary outcome variables for assessing the progression of OA.

Several indices are currently used for assessing radiological progression of OA, including individual radiographic features (e.g., marginal osteophytes), composite indices (e.g., Kellgren and Lawrence scoring systems), and quantitative measures (e.g., joint space width (JSW) measurement) (Salaffi F. *et al.*, Aging Clin. Exp. Res., 2003, 15(5): 391-404; Buckland-Wright, Osteoarthritis Cartilage, 1999, 7(4): 430-3). Regulatory agencies acknowledge that compounds may be granted a DMOAD indication, providing they demonstrate that they can slow down osteoarthritis disease progression; progression would be calibrated by a surrogate for structural change, by measuring joint space narrowing (JSN) on plain X-rays with the caveat that this delayed JSN translate into a clinical benefit for the patient. Recently, new Magnetic resonance imaging (MRI) technology has been developed to detect a structural change of the OA joint earlier than conventional X-rays and is now used to measure parameters of cartilage morphology and integrity in OA patients (Abadie E. *et al.*, Osteoarthritis Cartilage, 2004, 12(4): 263-8).

Without serial assessments using diagnostic techniques, OA may go undiagnosed until it is advanced. That is frequently the case in mammalian animals, like canidae, felidae or

equidae, for which OA is only identified when advanced symptoms appeared, notably lameness.

The present invention provides therapies for OA that utilize pharmaceutical compositions comprising vectors capable of expressing the BMP-7 polypeptide *in vivo* and methods and composition for inducing a sustained increase in synovial fluid BMP-7 concentration.

As used herein, a pharmaceutical composition according to the invention is said to have “therapeutic efficacy”, or to be “therapeutically effective”, if administration of that amount of the composition is sufficient to cause a significant improvement of the clinical signs or measurable markers of the disease in a mammalian subject suffering from OA. As used herein, a pharmaceutical composition according to the invention is said to have “prophylactic efficacy” or to be “effective”, if administration of that amount of the composition is sufficient to prevent the development of OA in a subject. The term “therapeutically effective” may also be used herein, in a more general sense, to refer to an amount of a composition that is either sufficient to cause a significant improvement of the clinical signs or measurable markers of disease in a mammalian subject suffering from OA, or that is sufficient to prevent the development of OA in a subject.

Experimental demonstration of the efficacy of the methods and compositions of the present invention (e.g. the methods and compositions useful for gene therapy with BMP-7 or functional equivalents of BMP-7), can be performed with a variety of measurable markers, for example, by demonstrating that humans treated using the methods and compositions of the present invention exhibit a significantly reduced diminution of joint space narrowing (JSN) measurement, as compared to placebo-treated humans, when suffering of OA, or by demonstrating that mammalian animals treated using the methods and compositions of the present invention exhibit a significant reduced lameness, and/or a significantly reduced diminution of cartilage thickness measurement on X-rays, as compared to placebo-treated mammalian animals, when suffering of OA. The measurement of cartilage thickness may also be done by echography on equidae.

In one aspect, the present invention relates to a vector capable of expressing, *in vivo* in a host, a Bone Morphogenetic Protein-7 (BMP-7) polypeptide, or a variant or a fragment thereof. As used herein “BMP-7 polypeptide” may be used to refer to pre-pro, pro or mature BMP-7 polypeptides, wherein the pro and mature BMP-7 polypeptides may be fused to a BMP-7, IGF-1 or tPA signal peptide. The BMP-7 polypeptides of the present invention are preferably of canine, feline, equine or human origin. In one embodiment the vector may

contain and express in the host a pre-proBMP-7, a proBMP-7 or a mature BMP-7 nucleotide sequence or gene. The nucleotide sequence or gene encoding the pre-proBMP-7 polypeptide, the proBMP-7 polypeptide or the mature BMP-7 polypeptide may originate from a mammal, for example a human, a cat, a horse or a dog. In a preferred embodiment the BMP-7

5 nucleotide sequence or gene may originate from a dog. In another preferred embodiment the BMP-7 nucleotide sequence or gene may originate from a cat. In another preferred embodiment the BMP-7 nucleotide sequence or gene may originate from a horse. In another preferred embodiment the BMP-7 nucleotide sequence or gene may originate from a human.

BMP-7 is also known as Osteogenic Protein-1 or “OP-1”, and is a member of the transforming growth factor- β or “TGF- β ” superfamily. It is a secreted protein that is processed from the pro-protein to yield the carboxy-terminal mature protein. Within the mature protein there is a conserved pattern of seven cysteine residues defining a domain that extends from amino acid 330 to amino acid 430 of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 19. The active form of the protein is a disulfide-bonded

15 homodimer. In its mature, native form, naturally occurring BMP-7 is a glycosylated dimer having an apparent molecular weight of about 30-36 kDa, as determined by SDS-polyacrylamide gel electrophoresis (“SDS-PAGE”). When reduced, the 30-36 kDa protein gives rise to two glycosylated polypeptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. The unglycosylated BMP-7 protein has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa unglycosylated protein gives rise to two unglycosylated polypeptide chains, having molecular weights of about 14 kDa and 16 kDa.

Typically, the naturally occurring BMP-7 protein is translated as a precursor, having an N-terminal signal peptide sequence, a “pro” domain, and a “mature” protein domain. The signal peptide is 29 residues long and is cleaved off rapidly upon translation at a cleavage site that can be predicted using the method of Von Heijne (1986), Nucleic Acid Research, 14; 4683-4691. The “pro” domain has 264 residues in human, canine, feline, swine and bovine BMP-7, and 263 residues in mouse BMP-7. The N-terminal part of the pro BMP-7 is cleaved to yield the “mature” C-terminal domain of 139 residues, which includes the conserved seven-cysteine C-terminal domain of 102 residues. As referred to herein, the “pro form” of the BMP-7 polypeptide refers to a protein comprising a pair of polypeptides, each comprising a pro domain in either covalent or non-covalent association with the mature domain of the BMP-7 polypeptide. The pro form appears to be the primary form secreted from cultured

mammalian cells. The “mature form” of the protein refers to the mature C-terminal domain which is not associated, either covalently or non-covalently, with the pro domain.

As used herein the terms “pre-pro BMP-7”, “pro BMP-7”, “mature BMP-7” and “BMP-7” refer not only to the specific polypeptides and sequences illustrated in the specification and in the accompanying sequence listing, but also refer to any and all of the known naturally occurring variants, of these proteins including, but not limited to, derivatives, mutants, homologues, orthologs, allelic variants, allelic polymorphs, polymorphic variants, phylogenetic counterparts, and also any and all non-naturally occurring variants of these proteins, including but not limited to derivatives, mutants, fragments, fusion proteins, and the like. As used herein, the term “variant” encompasses all such naturally occurring and non-naturally occurring variants. In particular, the present invention encompasses all such variants that retain the feature of being useful for the therapeutic or prophylactic treatment of OA, and/or that retain BMP-7 activity.

These functionally equivalent variants, derivatives, and fragments, and the like display the ability to retain BMP-7 activity. A functional equivalent, as used herein, refers to any BMP-7 variants, derivatives, fragments, and the like that meet either of the following two criteria (a) they have a significant level of amino acid sequence homology with the protein sequence of BMP-7 as described herein, or is encoded by a nucleotide that has a significant level of nucleotide sequence homology with the protein sequence of BMP-7 as described herein; or (b) they have the ability to provide a statistically different response in the treated group as compared to a placebo treated group in an experimental model of osteoarthritis in mammals, like for example the previously described post traumatic osteoarthritis model (PTOA model) (see Hurtig MB *et al.*, Proceedings Combined Orthopaedic Research Society, 070, October 2004 ; Bolam C.J. *et al.*, AJVR, 2006, 67(3): 433-447). In a typical PTOA model, animals were experimentally exposed to a standardized 30 MPa impact injuries to both (left and right) medial femoral condyles using a 3 cm minimally invasive arthrotomy at day 0 (D0). At day 7 (D7), half of the animals received a dose of 1 mL of a BMP-7 adenovirus vector (Ad5-BMP-7) according to the present invention (10^9 virus particles/mL) into the stifle joint of one bruised knee. The administration was done intra-articularly with a syringe and needle into the femoropatellar joint. Injection was done after synovial fluid (1 mL) was collected for various analysis. The contralateral bruised knee was not treated with Ad5-BMP-7. The second half of animals did not receive any treatment and remained as negative control. Serum and synovial fluid were harvested on D0, D14, D21, D28, D60 and D90. On D90, tissues were also collected for macroscopic examination and histology. The

results (i.e., lameness evolution, macroscopic data of the knee at necropsy on D90, histology results) on left and right knees were compared for each animal, and also versus the control animals. The animal models may be for example sheep (see Hurtig MB *et al.*, Proceedings Combined Orthopaedic Research Society, 070, October 2004) or horses (see Bolam C.J. *et al.*, AJVR, 2006, 67(3): 433-447).

By way of illustration of variants, derivatives, and the like that may be encompassed by the present invention include, but are not limited to, BMP-7 variants, derivatives, and the like that are encoded by nucleotide sequences that are not exactly the same as the nucleotide sequences disclosed herein, but wherein the changes in the nucleotide sequences do not change the encoded amino acid sequence, or result in conservative substitutions of amino acid residues, deletion of addition of one or a few amino acids, substitution of amino acid residues by amino acid analogues that do not significantly affect the properties of the encoded polypeptides, and the like. Examples of conservative amino acid substitutions include glycine/alanine substitutions; valine/isoleucine/leucine substitutions; asparagine/glutamine substitutions; aspartic acid/glutamic acid substitutions; serine/threonine/methionine substitutions; lysine/arginine substitutions; and phenylalanine/tyrosine/tryptophan substitutions. Other types of substitutions, variations, additions, deletions and derivatives that result in functional BMP-7 derivatives, as described above, are also encompassed by the present invention, and one of skill in the art would readily know how to make, identify, or select such variants or derivatives, and how to test for BMP-7 activity of those variants or derivatives. One of skill in the art may optimize the expression of the BMP-7 polypeptides of the invention by removing cryptic splice sites, by adapting the codon usage, by introducing a Kozak consensus sequence before the start codon, by changing the codon usage or combination thereof to improve expression.

In another embodiment, the present invention may comprise a functional equivalent of a canine pre-proBMP-7 polypeptide having at least 97.5 %, at least 98 %, at least 98.5 % or at least 99 % homology or identity with residues 1 to 431 of SEQ ID NO: 3.

In another embodiment, the present invention may comprise a functional equivalent of a human pre-proBMP-7 polypeptide having at least 98 %, at least 98.5 % or at least 99 % homology or identity with residues 1 to 431 of SEQ ID NO: 15.

In another embodiment, the present invention may comprise a functional equivalent of a feline pre-proBMP-7 polypeptide having at least 98.5 % or at least 99 % homology or identity with residues 1 to 431 of SEQ ID NO: 19.

51440-134

In another embodiment, the present invention may comprise a functional equivalent of an equine pre-proBMP-7 polypeptide having at least 97.5 %, at least 98 %, at least 98.5 % or at least 99 % homology or identity with residues 1 to 431 of SEQ ID NO: 16.

For the purposes of the present invention, sequence identity or homology may be
 5 determined by comparing the sequences when aligned so as to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity may be determined using any of a number of mathematical algorithms. A non-limiting example of a mathematical algorithm used for comparison of two sequences is the algorithm of Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1990, 87: 2264-2268, modified as in Karlin & Altschul, Proc. Natl.
 10 Acad. Sci. USA 1993, 90: 5873-5877.

Another example of a mathematical algorithm used for comparison of sequences is the algorithm of Myers & Miller, CABIOS 1988,4, 11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a
 15 PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson & Lipman, Proc. Natl. Acad. Sci. USA 1988, 85, 2444-2448.

Advantageous for use according to the present invention is the WU-BLAST
 20 (Washington University BLAST) version 2.0 software. WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. This program is based on WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul & Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266, 460-480; Altschul et al.,
 25 Journal of Molecular Biology 1990, 215, 403-410; Gish & States, Nature Genetics, 1993, 3: 266-272; Karlin & Altschul, 1993, Proc. Natl. Acad. Sci. USA 90, 5873-5877).

In general, comparison of amino acid sequences may be accomplished by aligning an amino acid sequence of a polypeptide of a known structure with the amino acid sequence of a
 30 the polypeptide of unknown structure. Amino acids in the sequences are then compared and groups of amino acids that are homologous are grouped together. This method detects conserved regions of the polypeptides and accounts for amino acid insertions and deletions. Homology between amino acid sequences can be determined by using commercially available algorithms (see also the description of homology above). In addition to those

otherwise mentioned herein, mention is made too of the programs BLAST, gapped BLAST, BLASTN, BLASTP, and PSI-BLAST, provided by the National Center for Biotechnology Information. These programs are widely used in the art for this purpose and can align homologous regions of two amino acid sequences.

5 In all search programs in the suite, the gapped alignment routines are integral to the database search itself. Gapping can be turned off if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer. Any
10 combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

In a preferred embodiment, the present invention provides a vector that comprises, as
15 insert, a polynucleotide that encodes a canine pre-proBMP-7 polypeptide, and more preferably that contains a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO: 3. Preferably this vector contains nucleotides 1 to 1296 of SEQ ID NO: 1.

In another preferred embodiment, the present invention provides a vector that
20 comprises, as insert, a polynucleotide that encodes a human pre-proBMP-7 polypeptide, and more preferably that contains a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO: 15. Preferably this vector contains nucleotides 1 to 1296 of SEQ ID NO: 13.

In another preferred embodiment, the present invention provides a vector that
25 comprises, as insert, a polynucleotide that encodes a feline pre-proBMP-7 polypeptide, and more preferably that contains a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO: 19. Preferably this vector contains nucleotides 1 to 1296 of SEQ ID NO: 17.

In another preferred embodiment, the present invention provides a vector that
30 comprises, as insert, a polynucleotide that encodes an equine pre-proBMP-7 polypeptide, and more preferably that contains a polynucleotide that encodes a polypeptide having the amino acid sequence of SEQ ID NO: 16. Preferably this vector contains nucleotides 1 to 1296 of SEQ ID NO: 10.

In one embodiment, the peptide signal (prepeptide) sequence spans from the Met residue at position (1) to the Ala residue at position (29), with the numbering of the amino acid residues being that of the pre-proBMP-7 sequence identified as SEQ ID NO: 3, 15, 16 or 19. Cleavage of the signal peptide may occur after the Ala(29) residue. After cleavage of the preBMP-7 peptide, the proBMP-7 polypeptide is secondarily cleaved after the sequence Arg-X-X-Arg(292) to lead to the mature BMP-7 polypeptide.

The terms “protein”, “polypeptide” and “polypeptide fragment” are used interchangeably herein to refer to polymers of amino acid residues of any length.

In certain embodiments, the expression vector may comprise a polynucleotide that encodes a mature BMP-7 polypeptide, wherein the polypeptide is fused to a peptide signal sequence that is, or that comprises or is derived from the BMP-7 signal peptide. In other embodiments, the signal peptide sequence may be, or comprise or be derived from, other signal peptides.

The present invention further relates to vectors containing and expressing a polynucleotide encoding the proBMP-7 polypeptide, wherein the pre-BMP-7 signal peptide is deleted and wherein a peptide signal sequence from a different origin is fused to the proBMP-7 polypeptide. For example, in certain embodiments, the peptide signal sequence may be the insulin-like growth factor 1 (IGF-1) or the tissue plasminogen activator (tPA) peptide signal sequence. In a preferred embodiment the proBMP-7 encoded by the polynucleotide is a canine proBMP-7 polypeptide. Advantageously the proBMP-7 is encoded by a polynucleotide nucleotide that is, or comprises, or is derived from nucleotides 88 to 1296 of SEQ ID NO: 1, and that encodes, or comprises an amino acid sequence corresponding to amino acid residues 30 to 431 of SEQ ID NO: 3. In another preferred embodiment, the codon-optimized canine nucleotide sequence corresponding to SEQ ID NO: 2 is used.

In another preferred embodiment the proBMP-7 encoded by the polynucleotide is a human proBMP-7 polypeptide. Advantageously the proBMP-7 is encoded by a polynucleotide nucleotide that is, or comprises, or is derived from nucleotides 88 to 1296 of SEQ ID NO: 13, and that encodes, or comprises an amino acid sequence corresponding to amino acid residues 30 to 431 of SEQ ID NO: 15. In another preferred embodiment, the codon-optimized human nucleotide sequence corresponding to SEQ ID NO: 14 is used.

In another preferred embodiment the proBMP-7 encoded by the polynucleotide is a feline proBMP-7 polypeptide. Advantageously the proBMP-7 is encoded by a polynucleotide that is, or comprises, or is derived from nucleotides 88 to 1296 of SEQ ID NO: 17, and that encodes, or comprises an amino acid sequence corresponding to amino acid

residues 30 to 431 of SEQ ID NO: 19. In another preferred embodiment, the codon-optimized feline nucleotide sequence corresponding to SEQ ID NO: 18 is used.

In another preferred embodiment the proBMP-7 encoded by the polynucleotide is an equine proBMP-7 polypeptide. Advantageously the proBMP-7 is encoded by a polynucleotide that is, or comprises, or is derived from nucleotides 88 to 1296 of SEQ ID NO: 10, and that encodes, or comprises an amino acid sequence corresponding to amino acid residues 30 to 431 of SEQ ID NO: 16.

Codon preference among different species can be dramatically different. To enhance the expression level of a foreign protein, it is relevant to match the codon frequency of the foreign protein to the one of the host expression system (Kim et al., Gene, 1997, 199(1-2): 293-301). Codon optimization also optimizes the stability of mRNAs and their export process to the cytoplasm. For codon optimization, other factors than codon frequency can be taken into consideration, e.g. DNA motifs and repeats, secondary structure, GC content, repetitive codons, restriction endonuclease sites, functional motifs like splice site or terminator structure. Algorithms have been created to facilitate the design of the optimal nucleotide sequence. Geneart GmbH (Regensburg, Germany) has developed the proprietary GeneOptimizer™ software (WO-A-04/059556 and WO-A-06/013103) that implements multi-parameter optimization in one single operation. Taking into account the most important parameters in parallel, the software generates a total of up to 500,000 optimized variants of the target sequence in an evolutionary approach and selects the one that is best suited. It has been reported that such optimized genes have up to a 100-fold increase in expression yields compared to the original gene sequence (Bradel-Tretheway et al., J. Virol. Methods, 2003, 111(2): 145-56; Disbrow et al., Virology, 2003, 311(1): 105-14). In embodiments where the nucleotide sequences are codon-optimized, the codon-optimization may be done by Geneart GmbH (Regensburg, Germany) using the GeneOptimizer™ software. The codon-optimization changes only the nucleic acid sequence and not the encoded amino acid sequence.

In embodiments where the signal peptide is derived from the IGF-I signal peptides, it is preferred that the peptide signal may be, or may comprise, or may be derived from, the horse IGF-1 peptide signal, and preferably that defined by amino acid residues 1 to 25 of SEQ ID NO: 9, and encoded by nucleotides 1 to 75 of SEQ ID NO: 8. In alternate embodiments, the IGF-1 peptide signal may be, or may comprise, or may be derived from, the canine IGF-1 peptide signal, and preferably is, or comprises, or is derived from, the

canine IGF-1 peptide signal defined by amino acid residues 1 to 25 of SEQ ID NO: 12, and that is encoded by nucleotides 1 to 75 of SEQ ID NO: 11.

In other embodiments, the peptide signal may be, or may comprise, or may be derived from, the tPA peptide signal, such as the human tPA signal peptide. In a preferred
 5 embodiment, the tPA signal peptide used, is, or comprises or is derived from, amino acid residues 1 to 23 of the human tPA signal peptide sequence of SEQ ID NO: 5, and is encoded by nucleotides 1 to 69 of SEQ ID NO: 4. In an alternative embodiment, a human tPA signal peptide may be, or may comprise, or may be derived from, amino acid residues 1 to 28 of SEQ ID NO: 7 and is encoded by nucleotides 1 to 84 of SEQ ID NO: 6 may be used.

10 According to an advantageous embodiment of the invention, the expression vector may comprise the polynucleotides encoding the signal peptide of IGF1 or tPA according to SEQ ID NO: 5, 7, 9 or 12 fused to the pre-proBMP-7 polypeptide deleted of the signal peptide (corresponding to residue 30 to residue 431). According to another embodiment of the invention, the expression vector comprises the polynucleotides encoding the signal
 15 peptide of IGF1 or tPA fused to the mature BMP-7 (corresponding to residue 293 to residue 431).

In some embodiments, the present invention encompasses a vector capable of expressing canine pre-proBMP-7, canine proBMP-7, canine mature BMP-7, human pre-proBMP-7, human proBMP-7, human mature BMP-7, equine pre-proBMP-7, equine
 20 proBMP-7, equine mature BMP-7, feline pre-proBMP-7, feline proBMP-7, feline mature BMP-7, or a variant or fragment thereof. For the mature BMP-7 or the proBMP-7, it is preferred that the nucleotide sequence encoding the peptide is preceded immediately by a nucleotide sequence in-frame encoding a peptide signal in order to facilitate the secretion of BMP-7 into the extra cellular medium. The signal sequence can be the natural sequence from
 25 the pre-proBMP-7 or a peptide signal from a secreted protein e.g. the signal peptide from the tissue plasminogen activator protein (tPA), in particular the human tPA (S. Friezner Degen et al J. Biol. Chem. 1996, 261, 6972-6985; R. Rickles et al J. Biol. Chem. 1988, 263, 1563-1569; D. Berg. et al Biochem. Biophys. Res. Commun. 1991, 179, 1289-1296), or the signal peptide from the Insulin-like growth factor 1 (IGF1), in particular the equine IGF1 (K. Otte et
 30 al. Gen. Comp. Endocrinol. 1996, 102(1), 11-15), the canine IGF1 (P. Delafontaine et al. Gene 1993, 130, 305-306), the feline IGF1 (WO-A-03/022886), the bovine IGF1 (S. Lien et al. Mamm. Genome 2000, 11(10), 877-882), the porcine IGF1 (M. Muller et al. Nucleic Acids Res. 1990, 18(2), 364), the chicken IGF1 (Y. Kajimoto et al. Mol. Endocrinol. 1989, 3(12), 1907-1913), the turkey IGF1 (GenBank accession number AF074980). The signal

peptide from IGF1 may be natural or optimized, in particular optimized by removing cryptic splice sites and/or by adapting the codon usage.

As used herein the term “polynucleotide” is used to refer to a polymeric form of nucleotides of any length, which contain deoxyribonucleotides or ribonucleotides.

5 The present invention further encompasses a vector containing and expressing a polynucleotide encoding a BMP-7 polypeptide operably linked to a promoter element and optionally also linked to an enhancer. In an advantageous embodiment, the promoter is the promoter of the cytomegalovirus (CMV) immediate early gene, preferably from human- or murine-derived CMV. In other embodiments, the enhancers and/or promoters may be
10 selected from among those promoters that are known in the art, and that are suitable for expression of BMP-7 in the vectors of the present invention. Many such promoters are known in the art, and suitable promoters can readily be selected by those of skill in the art. For example, there are various cell and/or tissue specific promoters (e.g., muscle, endothelial cell, liver, somatic cell, and stem cell specific promoters), and various viral promoters and
15 enhancers, and BMP-7 promoters, such as those isogenically specific for each animal species. For example, in one embodiment, if the canine BMP-7 is to be expressed in a canine synoviocytes, the enhancers and/or promoters specific to canine synoviocytes may be used in order to optimize expression of canine BMP-7 for the desired application.

 Promoters and enhancers that may be employed in the present invention include, but
20 are not limited to the promoters and enhancers of the LTR of Rous sarcoma virus, the TK gene of HSV-1, the early or late promoters of SV40, the adenovirus major late promoter (MLP), phosphoglycerate kinase genes, metallothionein genes, α -1 antitrypsin genes, albumin genes, collagenase genes, elastase I genes, β -actin genes, β -globin genes, γ -globin genes, α -fetoprotein genes, and muscle creatin kinase genes.

25 In general, it is advantageous to employ a strong promoter functional in eukaryotic cells. The preferred strong promoter is the immediate early cytomegalovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin such as the rat or guinea pig. The CMV-IE promoter can comprise the actual promoter part, which may or may not be associated with the enhancer part. Reference can be made to EP-A-260 148, EP-A-323 597,
30 U.S. Patents Nos. 5,168,062, 5,385,839, and 4,968,615, as well as to PCT Application No. WO87/03905. The CMV-IE promoter is advantageously a human CMV-IE (Boshart M. et al., Cell., 1985, 41, 521-530) or murine CMV-IE.

 In more general terms, the promoter has either a viral or a cellular origin. A strong viral promoter other than CMV-IE that may be usefully employed in the practice of the

invention is the early/late promoter of the SV40 virus or the LTR promoter of the Rous sarcoma virus. A strong cellular promoter that may be usefully employed in the practice of the invention is the promoter of a gene specific to synoviocytes.

Functional sub fragments of these promoters, i.e., portions of these promoters that
5 maintain an adequate promoting activity, are included within the present invention, e.g. truncated CMV-IE promoters according to PCT Application No. WO98/00166 or U.S. Patent No. 6,156,567 can be used in the practice of the invention. A promoter in the practice of the invention consequently includes derivatives and sub fragments of a full-length promoter that maintain an adequate promoting activity and hence function as a promoter, preferably
10 promoting activity substantially similar to that of the actual or full-length promoter from which the derivative or sub fragment is derived, e.g., akin to the activity of the truncated CMV-IE promoters of U.S. Patent No. 6,156,567 to the activity of full-length CMV-IE promoters. Thus, a CMV-IE promoter in the practice of the invention can comprise or consist essentially of or consist of the promoter portion of the full-length promoter and/or the
15 enhancer portion of the full-length promoter, as well as derivatives and sub fragments.

Preferably, the vectors comprise other expression control elements. It is particularly advantageous to incorporate stabilizing sequence(s), e.g., intron sequence(s), preferably the first intron of the hCMV-IE (PCT Application No. WO89/01036), the intron II of the rabbit β -globin gene (van Ooyen et al., Science, 1979, 206, 337-344). As to the polyadenylation
20 signal (polyA) for the viral vectors other than poxviruses, use can more be made of the poly(A) signal of the bovine growth hormone (bGH) gene (*see* U.S. Patent No. 5,122,458), or the poly(A) signal of the rabbit β -globin gene or the poly(A) signal of the SV40 virus.

The term “vector”, as used herein, refers to a recombinant adenovirus that comprises a heterologous polynucleotide to be delivered to a target cell, such as *in vivo*. The heterologous
25 polynucleotide may comprise a sequence of interest for purposes of therapy, and may optionally be in the form of an expression cassette. The heterologous polynucleotide may comprise additional sequences, such as additional coding sequences within the same transcription unit, controlling elements such as promoters, ribosome binding sites, transcription terminators, polyadenylation sites, additional transcription units under control of
30 the same or different promoters, sequences that permit cloning, expression, homologous recombination, and transformation of a host cell, and any such construct as may be desirable to provide embodiments of this invention.

The term “recombinant” as used herein means a polynucleotide semisynthetic, or synthetic origin, which either does not occur in nature or is linked to another polynucleotide in an arrangement not found in nature.

The term “heterologous” as used herein derived from a genetically distinct entity from the rest of the entity to which it is being compared. For example, a polynucleotide may be placed by genetic engineering techniques into a plasmid or vector derived from a different source, and is thus a heterologous polynucleotide. A promoter removed from its native coding sequence and operatively linked to a coding sequence other than the native sequence is accordingly a heterologous promoter.

Elements for the expression of canine BMP-7 or feline BMP-7 or human BMP-7 or equine BMP-7 are advantageously present in an inventive vector. In a minimum manner, this may comprise, may consist essentially of, or may consist of an initiation codon (ATG), a stop codon and a promoter, and optionally also a polyadenylation sequence for certain vectors such as, e.g., viral vectors other than poxviruses. When the polynucleotide encodes a polypeptide fragment, e.g. canine BMP-7, advantageously, in the vector, an ATG may be placed at 5' of the reading frame and a stop codon may be placed at 3'. Other elements for controlling expression may be present, such as enhancer sequences, stabilizing sequences, such as intron and signal sequences permitting the secretion of the protein.

Methods for making and/or administering a vector or recombinants for expression of gene products of genes of the invention *in vivo* can be any desired method, e.g., a method which is by or analogous to the methods disclosed in, or disclosed in documents cited in: Chroboczek J *et al.*, Virol. 1992, 186: 280-285; Yarosh *et al.*, Vaccine, 1996, 14(13):1257-64; Lutze-Wallace *et al.*, Biologicals, 1995, 23(4):271-7; Falloux F. *et al.*, Human Gene Therapy, 1998, 9: 1909-1917; Shriver J. *et al.*, Nature, 2002, 415: 331-335; Graham F. *et al.*, Methods in Molecular Biology, Vol .7: Gene Transfer and Expression Protocols Edited by E. Murray, The Human Press Inc, 1991, p 109-128; Ilan Y. *et al.*, Proc. Natl. Acad. Sci., 1997, 94: 2587-2592; Tripathy S. *et al.*, Proc. Natl. Acad. Sci., 1994, 91: 11557-11561; Tapnell B., Adv. Drug Deliv. Rev., 1993, 12: 185-199; Danthinne X. *et al.*, Gene Therapy, 2000, 7: 1707-1714; Berkner K., Bio Techniques, 1988, 6: 616-629; Berkner K. *et al.*, Nucl. Acid Res., 1983, 11 : 6003-6020; Chavier C. *et al.*, J. Virol., 1996, 70: 4805-4810.

According to one embodiment of the invention, the expression vector may be a viral vector, in particular an *in vivo* expression vector. In an advantageous embodiment, the expression vector may be an adenovirus vector. Advantageously, the adenovirus may be a human adenovirus type 5 (hAd5) vector, an E1-deleted and/or an E3-deleted hAd5.

Advantageously, the adenovirus may be a canine adenovirus type 2 (CAV-2) vector, an E3-deleted CAV-2 and/or an inserted CAV-2 in the region located between the E4 region and the right ITR region.

In one embodiment the viral vector may be a human adenovirus, in particular a serotype 5 adenovirus, rendered incompetent for replication by a deletion in the E1 region of the viral genome, in particular from about nucleotide 459 to about nucleotide 3510 by reference to the sequence of the hAd5 disclosed in Genbank under the accession number M73260 and in the referenced publication J. Chroboczek et al Virol. 1992, 186, 280-285. The deleted adenovirus can be propagated in either the E1-expressing HEK293 (F. Graham et al J. Gen. Virol. 1977, 36, 59-72) or PER cells, in particular PER.C6 cell lines (F. Falloux et al Human Gene Therapy 1998, 9, 1909-1917). Alternatively, the Ad5 vector can be propagated in any cell line providing transcomplementation for the viral deleted E1 genomic region. The human adenovirus can also be deleted in the E3 region, in particular from about nucleotide 28592 to about nucleotide 30470. Further, the deletion in the E1 region can be done in combination with a deletion in the E3 region (*see, e.g.* J. Shriver et al. Nature, 2002, 415, 331-335, F. Graham et al Methods in Molecular Biology Vol .7: Gene Transfer and Expression Protocols Edited by E. Murray, The Human Press Inc, 1991, p 109-128; Y. Ilan et al Proc. Natl. Acad. Sci. 1997, 94, 2587-2592; US6,133,028; US6,692,956; S. Tripathy et al Proc. Natl. Acad. Sci. 1994, 91, 11557-11561; B. Tapnell Adv. Drug Deliv. Rev.1993, 12, 185-199; X. Danthinne et al Gene Thrapy 2000, 7, 1707-1714; K. Berkner Bio Techniques 1988, 6, 616-629; K. Berkner et al Nucl. Acid Res. 1983, 11, 6003-6020; C. Chavier et al J. Virol. 1996, 70, 4805-4810). The insertion sites can be the E1 and/or E3 loci (region) eventually after a partial or complete deletion of the E1 and/or E3 regions. Advantageously, the polynucleotide to be expressed is inserted under the control of a promoter functional in eukaryotic cells, such as a strong promoter, preferably a cytomegalovirus immediate-early gene promoter (CMV-IE promoter), in particular the enhancer/promoter region from about nucleotide -734 to about nucleotide +7 in M. Boshart et al Cell 1985, 41, 521-530 or the enhancer/promoter region from the pCI vector from PROMEGA Corp. The CMV-IE promoter is advantageously of murine or human origin. The promoter of the elongation factor 1 α can also be used. Strong promoters are also discussed herein in relation to plasmid vectors. In one embodiment, a splicing sequence can be located downstream of the enhancer/promoter region. For example, the intron 1 isolated from the CMV-IE gene (R. Stenberg et al J. Virol. 1984, 49, 190), the intron isolated from the rabbit or human β -globin gene, in particular the intron 2 from the β -globin gene, the intron isolated from the

immunoglobulin gene, a splicing sequence from the SV40 early gene or the chimeric intron sequence isolated from the pCI vector from Promega Corp. comprising the human β -globin donor sequence fused to the mouse immunoglobulin acceptor sequence (from about nucleotide 890 to about nucleotide 1022 in Genbank under the accession number

5 CVU47120). A poly(A) sequence and terminator sequence can be inserted downstream the polynucleotide to be expressed, e.g. a bovine growth hormone gene, in particular from about nucleotide 2339 to about nucleotide 2550 in Genbank under the accession number BOVBMP-7, a rabbit β -globin gene or a SV40 late gene polyadenylation signal.

In another embodiment the viral vector may be a canine adenovirus (CAV), in particular a CAV-2 (see, e.g. L. Fischer et al. Vaccine, 2002, 20, 3485-3497; U.S. Patent No. 10 5,529,780; U.S. Patent No. 5,688,920; PCT Publication No. WO95/14102). For CAV, the insertion sites can be in the E3 region and/or in the region located between the E4 region and the right ITR region (see U.S. Patent No. 6,090,393; U.S. Patent No. 6,156,567). In one embodiment, the vector may be CAV-2 and the insert may be the nucleic acid sequence encoding the canine pre-proBMP-7, the canine proBMP-7 or the canine mature BMP-7 15 polypeptide, under the control of a promoter, such as a cytomegalovirus immediate-early gene promoter (CMV-IE promoter) or a promoter already described for a human adenovirus vector. A poly(A) sequence and terminator sequence can be inserted downstream the polynucleotide to be expressed, e.g. a bovine growth hormone gene or a rabbit β -globin gene 20 polyadenylation signal.

Each human adenovirus vector may comprise or may contain or may consist essentially of, in addition to the polynucleotide encoding the pre-proBMP-7, the proBMP-7 or the mature BMP-7 polypeptide, the BMP-7 polypeptide being preferably from canine origin, equine origin, feline origin, human origin, variant, analog or fragment, operably linked 25 to a promoter or under the control of a promoter or dependent upon a promoter.

The present invention also relates to a pharmaceutical composition comprising a vector expressing *in vivo* under appropriate or suitable conditions or in a suitable host cell. The pharmaceutical compositions may comprise, may consist essentially of, or may consist of one or more vectors, e.g., expression vectors, such as *in vivo* expression vectors, comprising, 30 consisting essentially or consisting of and expressing one or more polynucleotides encoding a BMP-7 polypeptide, optionally fused with a BMP-7, IGF-1 or tPA signal peptide, in a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle. Advantageously, the vector may be a human adenovirus and may comprise, may consist essentially of, or may consist of and expresses at least one polynucleotide encoding a canine BMP-7 polypeptide or

an equine BMP-7 polypeptide or a feline BMP-7 polypeptide or a human BMP-7 polypeptide, optionally fused with a BMP-7, IGF-1 or tPA signal peptide, in a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle. Thus, according to an embodiment of the invention, the other vector or vectors in the composition may comprise a polynucleotide that encodes, and under appropriate circumstances expresses one or more other proteins, polypeptides or peptides than the canine BMP-7 polypeptide or an equine BMP-7 polypeptide or a feline BMP-7 polypeptide or a human BMP-7 polypeptide.

Compositions containing one or more vectors, may comprise, may consist essentially of, or may consist of polynucleotides encoding, and advantageously expressing, *in vivo*, a canine BMP-7 polypeptide or an equine BMP-7 polypeptide or a feline BMP-7 polypeptide or a human BMP-7 polypeptide or fusion protein thereof.

In an advantageous embodiment, the invention may provide for the administration of a therapeutically effective amount of a formulation for the delivery and expression of a BMP-7 polypeptide in a target cell. In one embodiment, the formulation comprises an expression vector comprising a polynucleotide that expresses BMP-7 polypeptide and a pharmaceutically or veterinarily acceptable carrier, vehicle or excipient. In an advantageous embodiment, the pharmaceutically or veterinarily acceptable carrier, vehicle or excipient may facilitate transfection and/or may improve preservation of the vector.

For example, a pharmaceutically or veterinarily acceptable carrier or vehicle or excipient can be water or a 0.9% NaCl (e.g., saline) solution or a phosphate buffer. Other pharmaceutically or veterinarily acceptable carrier or vehicle or excipients that can be used for methods of this invention include, but are not limited to, poly(L-glutamate) or polyvinylpyrrolidone. For Ad5 vector, a pharmaceutically or veterinarily acceptable carrier or vehicle or excipient is Tris HCl 10 mM, MgCl₂ 1 mM, NaCl 150 mM, Tween-80 54 mg/L, Saccharose 1 M, pH8.5. The pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector, increasing the level of expression or increasing the duration of expression. Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.

Ad5 virus vectors, as other replication-defective recombinant adenovirus vectors, are limited by their propensity to provoke strong innate and adaptive immune responses. Indeed, development of humoral immune responses to the vector by the host leads to neutralizing antibodies and has been shown to preclude efficacy of repeat administrations.

Covalent attachment of polyethylene glycol polymer (PEG) to the surface of the Ad5 virus is a strategy to circumvent neutralizing antibodies by masking the surface of the vector. As PEGylation of Ad5 is compatible with virus infectivity and masks the virus from neutralizing antibodies, PEGylation improves the ability to administer the Ad5 vector on
5 repeated basis.

In a particular embodiment of the invention, the Ad5 virus vector may be PEGylated, that is to say that PEG polymers are covalently attached to the surface of the Ad5 virus.

Such PEGylation may be done by a method comprising the following steps:

- (1) Covalent attachment of PEG to the surface of the Ad5 can be achieved using
10 activated PEG tresylmonomethoxypolyethylene glycol (TMPEG) which reacts preferentially with epsilon-amino terminal of lysine residues of viral hexon, fiber and penton base while preserving a particule to infectious unit ration below 100. TMPEG manufactured according to the procedure of Delgado C. et al., Biotechnol. Appl. Biochem., 1990, 12(2):119-28 can be sourced commercially from Shearwater
15 Polymers (Huntsville, AL). The advantage of TMPEG is related to the fact that it can drive coupling under mild physiological conditions, resulting in greater bioactivity.
- (2) Prior to PEGylation with TMPEG, virus preparations (in PBS 5% sucrose) are diluted twofold with 130mM sodium phosphate, pH7, containing 5% sucrose to a final particle concentration of virus of approximatively 1×10^{12} particules/ml.
- 20 - (3) In order to maintain highest infectivity of the virus PEGylation is performed using a PEG-to-virus ratio of 5:1 (mole:mole) using TMPEG at 5% (w/v). PEG coupling reaction is performed on a rotary mixer at room temperature (usually 23-24°C) during 30 minutes. The reaction is subsequently stopped by lowering the temperature of the reaction to 4°C.
- 25 - (4) In order to increase the level of PEGylation with TMPEG, the starting TMPEG can be increased to 10% (w/v) during 30 minutes. However this procedure is associated to a reduction in pH that is deleterious to both the virus and the reaction. Since controlling the pH is key, reaction can be performed in 130 mM phosphate, pH7 which provides pH stability over 2 hours and therefore allows PEGylation using 10%
30 TMPEG.
- (5) PEGylated vector is subsequently separated from unreacted PEG by CsCl gradient centrifugation or by dialysis against PBS-sucrose (5%).

In a specific embodiment, the pharmaceutical composition may be directly administered *in vivo* into the joint to be treated, and the encoded product is expressed by the

51440-134

vector in the host articulation. The methods to deliver intra-articularly *in vivo* a vector encoding a BMP-7 polypeptide, advantageously the canine BMP-7 polypeptide or the equine BMP-7 polypeptide or the feline BMP-7 polypeptide or the human BMP-7 polypeptide, can be modified to deliver the BMP-7 polypeptide, of the present invention to a human, a
 5 canidae, an equidae or a felidae notably man, woman, child, dog, bitch, puppy, horse, mare, foal, cat or kitten. The intra-articular *in vivo* delivery of a vector encoding and expressing the BMP-7 described herein can be accomplished by one of ordinary skill of human or veterinary medicines.

Advantageously, the pharmaceutical compositions and/or formulations according to
 10 the invention comprise or consist essentially of or consist of an effective quantity of one or more expression vectors to elicit a therapeutic response as discussed herein; and, an effective quantity can be determined from this disclosure, and the knowledge in the art, without undue experimentation.

The therapeutic and/or pharmaceutical composition contains per dose from about 10^7
 15 to about 10^{11} , advantageously from about 10^8 to about 10^{10} and more advantageously from about 10^9 to about 10^{10} viral particles (VP) of recombinant human adenovirus expressing BMP-7 polypeptide. The above described dose ranges remain available if the therapeutic and/or pharmaceutical compositions are based on PEGylated human adenovirus vector, notably on PEGylated hAd5 vector. In the case of therapeutic and/or pharmaceutical
 20 compositions based on a canine adenovirus vector, notably on CAV-2 vector, a dose can be between about 10^5 VP and about 10^9 VP, advantageously between about 10^6 and about 10^8 , more advantageously between about 10^6 and about 10^7 VP of recombinant canine adenovirus expressing canine BMP-7 polypeptide. Titers of adenovirus expressed in virus particles (VP) could be determinate by HPLC and chromatography as describe in paragraph 2.3 of Roitsch
 25 C. *et al.*, J Chromatography, 2001, 752: 263-280.

The dose volume of compositions for mammals, e.g., the dose volume of canine compositions, based on adenovirus vectors may be generally between about 0.1 to about 2.0 ml, preferably between about 0.1 to about 1.0 ml, and more preferably between about 0.5 ml to about 1.0 ml.

30 The present invention may contemplate at least one administration to a mammal of an efficient amount of the therapeutic composition made according to the invention. The mammal may be male, female, pregnant female. In an advantageous embodiment, the mammal may be a human, a canidae or an equidae or a felidae, notably man, woman, child, dog, bitch, puppy, horse, mare, foal, cat, queen or kitten.

The therapeutic composition according to the invention can be administered intra-articularly by a syringe and a needle. The administration may be done by passing through the synovial lining of the articulation to be treated and by injecting the therapeutic composition according to the invention into the synovial fluid.

5 It should be understood by one of skill in the art that the disclosure herein regarding administration of the compositions of the invention is provided by way of example, and that the present invention is not limited to the specific examples described. From the disclosure herein, and from the knowledge in the art, the skilled artisan can determine the number of administrations, the administration route, and the doses to be used for each administration of
10 the compositions of the present invention without any undue experimentation.

In a preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, a canine pre-proBMP-7, a canine proBMP-7, a canine BMP-7 mature polypeptide, human pre-proBMP-7, human proBMP-7, human mature BMP-7, equine pre-proBMP-7, a equine proBMP-7, a
15 equine BMP-7 mature polypeptide, feline pre-proBMP-7, feline proBMP-7, feline mature BMP-7, or a variant, derivative or fragment thereof, for the treatment and/or prevention of OA by intra-articular injection.

The pharmaceutical composition according to the present invention, comprising vectors capable of expressing the BMP-7 polypeptide *in vivo*, and which provides therapies
20 for OA, can also be administered to mammalian subjects, which are simultaneous treated with at least one active non steroidal anti-inflammatory drugs (NSAID'S) ingredient.

The present invention provides also a method of treating a mammalian subject suffering from osteoarthritis, comprising, administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one
25 pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle, recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter, wherein the mammalian subject is simultaneously treated with at least one active NSAID'S ingredient and the BMP-7 polypeptide is expressed *in vivo* in the mammalian subject.

30 In a particular embodiment, active NSAID'S ingredients are provided to the treated mammalian subjects between about 10 days before and about 10 days after the administration of the pharmaceutical composition comprising vectors capable of expressing the BMP-7 polypeptide *in vivo*. Preferably, active NSAID'S ingredients are provided between about 5 days before and about 5 days after the administration of the pharmaceutical composition

comprising vectors capable of expressing the BMP-7 polypeptide *in vivo*. Most preferably, active NSAID'S ingredients are provided between about 2 days before and about 2 days after the administration of the pharmaceutical composition comprising vectors capable of expressing the BMP-7 polypeptide *in vivo*.

5 The administration of NSAID'S may be done orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injection, intravenous, intramuscular, intrasternal injection or infusion techniques.

10 The pharmaceutical compositions containing the active NSAID'S ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may
15 contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active NSAID'S ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium
20 carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a
25 sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

 Formulations for oral use may also be presented as hard gelatin capsules wherein the
30 active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active NSAID'S material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethycellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum
5 acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as
10 polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or
15 aspartame.

Oily suspensions may be formulated by suspending the active NSAID'S ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and
20 flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active NSAID'S ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable
25 dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

The NSAID'S may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example,
30 liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The compositions of NSAID'S may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be

5 formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parentally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride
10 solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acid such as oleic acid fin use in the preparation of injectables.

NSAID'S compound may also be administered in the form of suppositories for rectal
15 administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the
20 NSAID'S compound are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about
25 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.

The amount of active NSAID'S ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the
30 particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between

from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet,
5 time of administration, route of administration, rate of excretion, drug combination and the severity of the osteoarthritis.

In a particular embodiment, the NSAID'S may be COX-2 (cyclooxygenase-2) inhibitors. The COX-2 inhibitors may be co-administered, as previously described, to the mammalian subject treated by intra-articular injection of a therapeutic composition according
10 to the present invention for the treatment and/or prevention of OA. As with other NSAIDs, COX-2 inhibitors are effective in treating cyclooxygenase mediated diseases such as inflammation, analgesia and fever. These compounds are especially effective in treating cancer, rheumatoid arthritis and osteoarthritis. These compounds have the advantage of not affecting the integrity of the gastrointestinal tract and the renal blood flow. Examples of these
15 compounds include (methylsulfonyl)phenyl-2-5(H)-furanone derivatives. These derivatives are described, for example, in US-B1-5.981.576. Preferably, the COX-2 inhibitors are selected among the compounds of Formula I as described in the granted patent US-B1-6.169.188. Especially preferred COX-2 inhibitors include 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or 3-(cyclopropylethoxy)-5,5-
20 dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or pharmaceutically acceptable salts or hydrates of these compounds. An especially preferred COX-2 inhibitor is polymorphic form B of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one.

For horses, the doses of COX-2 inhibitors may be from about 0.05 to about 0.5 mg/kg
25 per 12-24h as an oral or parenteral administration (notably intravenous, subcutaneous or intramuscular administration) and more preferably about 0.1 mg/kg per 24h. Preferably Cox-2 inhibitors are oral liquid suspension or solution, viscous liquid, gel, paste or intravenous/subcutaneous/intramuscular formulation.

For dogs, the doses of COX-2 inhibitors may be from about 2 to about 10 mg/kg per
30 12-24h, preferably from about 5 to about 10 mg/kg per 24h, and more preferably about 5 mg/kg per 24h. Preferably Cox-2 inhibitors are an oral tablet (classic hard, chewable or soft chewable), oral liquid suspension or solution, or intravenous/subcutaneous/intramuscular formulation.

Some examples of pastes comprising COX-2 inhibitors are described in the patent application EP-A1-1.688.149, notably in tables 10-12.

The present invention provides further therapies for OA that utilize pharmaceutical compositions comprising vectors capable of expressing *in vivo* the BMP-7 polypeptide and at least one interleukine-10 (IL10), and thereby providing methods and composition for inducing a sustained increase in synovial fluid BMP-7 concentration and IL10 concentration.

The present invention provides further a method of treating a mammalian subject suffering from osteoarthritis, comprising, administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle, recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter, and recombinant viral vectors containing a nucleic acid sequence encoding a IL10 polypeptide operatively linked to a promoter, wherein the BMP-7 polypeptide and the IL10 polypeptide are expressed *in vivo* in the mammalian subject.

In another particular embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, a canine pre-proBMP-7, a canine proBMP-7, a canine BMP-7 mature polypeptide, human pre-proBMP-7, human proBMP-7, human mature BMP-7, equine pre-proBMP-7, a equine proBMP-7, a equine BMP-7 mature polypeptide, feline pre-proBMP-7, feline proBMP-7, feline mature BMP-7, or a variant, derivative or fragment thereof, and another viral vector encoding and capable of expressing, interleukine-10 (IL10), notably equine IL10, canine IL10, feline IL10, human IL10, viral IL10 for the treatment and/or prevention of OA by intra-articular injection. In a preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, a canine pre-proBMP-7, a canine proBMP-7, a canine BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and another viral vector encoding and capable of expressing, canine IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, an equine pre-proBMP-7, an equine proBMP-7, an equine BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and another viral vector encoding and capable of expressing, equine IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, a feline pre-proBMP-7, a feline proBMP-7,

a feline BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and another viral vector encoding and capable of expressing, feline IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing, a human pre-proBMP-7, a human proBMP-7, a human BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and another viral vector encoding and capable of expressing, human IL10 for the treatment and/or prevention of OA by intra-articular injection. Preferably, the “another viral vector” is an adenovirus vector, notably a human adenovirus or a canine adenovirus, in particular hAd5 vector or CAV2 vector. When such combinations of vectors are used, the administration is done as previously described for compositions comprising only adenovirus vectors expressing BMP-7 polypeptide, except that the therapeutic and/or pharmaceutical composition contains per dose from about 10^7 to about 10^{11} VP of adenovirus vectors expressing BMP-7 polypeptide and from about 10^7 to about 10^{11} VP of adenovirus vectors expressing IL10 polypeptide; advantageously from about 10^8 to about 10^{10} VP of adenovirus vectors expressing BMP-7 polypeptide and from about 10^8 to about 10^{10} VP of adenovirus vectors expressing IL10 polypeptide; and more advantageously from about 10^9 to about 10^{10} VP of adenovirus vectors expressing BMP-7 polypeptide and from about 10^9 to about 10^{10} VP of adenovirus vectors expressing IL10 polypeptide. In the case of therapeutic and/or pharmaceutical compositions based on a canine adenovirus vector, notably on CAV-2 vector, a dose can be between about 10^5 VP and about 10^9 VP, advantageously between about 10^6 and about 10^8 , more advantageously between about 10^6 and about 10^7 VP of recombinant canine adenovirus.

The present invention provides further a method of treating a mammalian subject suffering from osteoarthritis, comprising, administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle, recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter and a nucleic acid sequence encoding a IL10 polypeptide operatively linked to a second promoter, wherein the BMP-7 polypeptide and the IL10 polypeptide are expressed in vivo in the mammalian subject.

In another particular embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing both, a canine pre-proBMP-7, a canine proBMP-7, a canine BMP-7 mature polypeptide, human pre-proBMP-7, human proBMP-7, human mature BMP-7, equine pre-proBMP-7, a equine

proBMP-7, a equine BMP-7 mature polypeptide, feline pre-proBMP-7, feline proBMP-7, feline mature BMP-7, or a variant, derivative or fragment thereof, and encoding and interleukine-10 (IL10), notably equine IL10, canine IL10, feline IL10, human IL10 for the treatment and/or prevention of OA by intra-articular injection. In a preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing both, a canine pre-proBMP-7, a canine proBMP-7, a canine BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and canine IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing both, an equine pre-proBMP-7, an equine proBMP-7, an equine BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and equine IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing both, a feline pre-proBMP-7, a feline proBMP-7, a feline BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and feline IL10 for the treatment and/or prevention of OA by intra-articular injection. In another preferred embodiment, the present invention relates to the use of, and to compositions comprising, a viral vector encoding and capable of expressing both, a human pre-proBMP-7, a human proBMP-7, a human BMP-7 mature polypeptide, or a variant, derivative or fragment thereof, and human IL10 for the treatment and/or prevention of OA by intra-articular injection. When such two insert vectors are used, the administration is done as previously described for compositions comprising only adenovirus vectors expressing BMP-7 polypeptide.

Nucleic acid sequences encoding IL10 can be found in Internet databases, notably in Genbank database under the accession number U38200 and region [1-537] for equine IL10, XM_850467.1 and region [2-541] for canine IL10, NM_001009209.1 and region [1-537] for feline IL10, NM_000572.2 and region [60-596] for human IL10, and AF182315 for viral IL10.

As defined for BMP-7, functional equivalents of IL10, variants of IL10, derivatives of IL10, and the like are encompassed by the present invention. Functional equivalents of IL10 are defined by the biological activities and properties of IL10, whose activities and properties are notably described in Schlaak JF *et al.*, J Immunol Methods, 1994, 168(1): 49-54.

In a particular embodiment, the present invention may comprise a functional equivalent of an equine IL10 polypeptide having at least 90 %, at least 91 %, at least 92 %, at

least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % homology or identity with SEQ ID NO: 60.

In another particular embodiment, the present invention may comprise a functional equivalent of a canine IL10 polypeptide having at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % homology or identity with SEQ ID NO: 62.

In another particular embodiment, the present invention may comprise a functional equivalent of a feline IL10 polypeptide having at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % homology or identity with SEQ ID NO: 64.

In another particular embodiment, the present invention may comprise a functional equivalent of a human IL10 polypeptide having at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % homology or identity with SEQ ID NO: 66.

In another particular embodiment, the present invention may comprise a functional equivalent of a viral IL10 polypeptide having at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % homology or identity with SEQ ID NO: 68.

The promoters for the expression of IL10 are the same than those described previously for BMP-7 expression.

The invention will now be further described by way of the following non-limiting examples.

EXAMPLES

Example 1: Generation of the feline BMP-7 gene.

The cDNA of the BMP-7 was obtained by RT-PCR using purified RNA from feline kidney cells. Total RNA was prepared from feline kidney cells obtained from kidney from foal using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's protocol.

The reverse transcriptase (RT) step was performed using the One Step Superscript III Kit (Invitrogen, New Jersey, USA, Ref: 12574.035) according to the manufacturer's protocol. The cDNA fragment corresponding to the feline BMP-7 gene was then amplified by polymerase chain reaction (PCR) using 2 couples of primers PB1053-PB1063 and PB1060-PB1062 according to the GenBank available sequences (human BMP-7 under the accession number AL122058, murine under the accession number NM_007557 and canine

under the accession number XM_862341).

PB1053 (SEQ ID NO: 20) (31 mer):

5' GGATCCCTAGTGGCAGCCACAGGCTCGGACG 3'

PB1063 (SEQ ID NO: 21) (24 mer):

5' GCCACCAGCAACCACTGGGTGGTC 3'

PB1060 (SEQ ID NO: 22) (24 mer):

5' TTCAGCCTGGACAACGAGGTGCAC 3'

PB1062 (SEQ ID NO: 23) (20 mer):

5' TGGTTGGTGGCGTTCATGTA 3'

The RT-PCR conditions were:

Cycle	Step1	Step2	Step3
1	52°C – 30 min		
2	94°C – 2 min		
3-48	94°C – 15 sec	Gradient of temperature (50°C-60°C) – 30 sec	68°C – 1 min 30
49	68°C – 5 min		

The last cycle was performed with the Taq Polymerase (Life Technologies, Cergy Pontoise, France) to allow an extra A to be incorporated at the 5' end of the transcripts.

The PCR fragment (698 base pairs (bp) – amplification with primers PB1053-PB1063) was purified from an agarose gel using UltraClean™ 15 DNA Purification Kit (MoBio Laboratories, Inc., USA) and cloned into the pCR2.1 vector (TA Cloning Kit, Invitrogen, ref: 45-0641) to generate the plasmid pPB759 (4546 bp).

The PCR fragment (1036 bp – amplification with primers PB1060-PB1062) was purified from an agarose gel using UltraClean™ 15 DNA Purification Kit (MoBio Laboratories, Inc., USA) and cloned into the pCR2.1 vector (TA Cloning Kit, Invitrogen, ref: 45-0641) to generate the plasmid pPB761 (4968 bp).

Plasmid pPB759 was digested with BstEII and NotI to obtain a BstEII-NotI fragment (394 bp). Plasmid pPB761 was digested with BstEII and NotI to obtain a BstEII-NotI fragment (4749 bp). The two fragments were ligated to generate plasmid pPB758 (5143 bp).

The identity of pPB758 was confirmed by BamHI and PstI digestions.

Cloning the 5' flanking region of the feline BMP-7 was based on the strong homology of the intron sequence downstream of the BMP-7 gene for the different species.

A semi-nested PCR was performed using the forward primer PB1088 localized in the sequence of the intron and two different reverse primers PB1089 and PB1090.

The first PCR was performed with primers PB1088-PB1089 and DNA genomic extract from CRFK cells (Crandell-Ress Feline Kidney cells) as template and the Phusion™ High-Fidelity DNA Polymerase (Finnzymes, ref: F-518).

The PCR conditions were:

Cycle	Step1	Step2	Step3
1	98°C – 30 sec		
2-30	98°C – 10 sec	Gradient of temperature (45°C-65°C) – 30 sec	72°C – 15 sec
31	68°C – 10 min		

The second PCR (nested PCR) was performed with primer PB1088 and primer PB1090 using the 100-fold diluted first PCR reaction as template. The reaction was allowed to proceed under the same conditions as those for the first reaction.

PB1088 (SEQ ID NO: 24) (23 mer):

5' GGGTAGCGCGTAGAGCCGGCGCG 3'.

PB1089 (SEQ ID NO: 25) (22 mer):

5' CGTCGGTGAGGAAGCGGCTCTA 3'.

PB1090 (SEQ ID NO: 26) (22 mer):

5' GGATCTCGCGCTGCATCTCCCG 3'.

The PCR fragment (190 bp-amplification with primers PB1088-PB1090) was purified from an agarose gel using UltraClean™ 15 DNA Purification Kit (MoBio Laboratories, Inc., USA) and cloned into the pCR2.1 vector (TA Cloning Kit, Invitrogen, ref: 45-0641) to generate the plasmid pPB770 (4129 bp).

The feline BMP-7 open reading frame (ORF) was entirely sequenced and the nucleotide sequence and amino acid sequence were given under the SEQ ID NO: 17 and SEQ ID NO: 19, respectively.

Example 2: Construction of the Ad5 adenovirus vector having murine BMP-7 insert.

The nucleic acid and amino acid sequences of the murine BMP-7 are available on GenBank database under the accession number NM_007557.

The murine BMP7 ORF consists of a nucleotide sequence of 1293 bp (SEQ ID NO: 27) and encodes a 430 amino acids polypeptide (SEQ ID NO: 28).

To prepare adenovirus vectors, the nucleotide sequence SEQ ID NO: 27 of the murine BMP-7 polypeptide was amplified by PCR using primers that add FseI and AscI restriction sites at the 5' and 3' termini, respectively. PCR primers were used with a template containing the full-length BMP-7 cDNA in a PCR reaction as follows: incubation at 95°C for 5 minutes;

followed by 15 cycles at 95°C for 1 min., 58°C for 1. min., and 72°C for 1.5 min.; followed by 72°C for 7 min.; followed by a 4°C soak. The reaction products were loaded onto a 1.2 % (low melt) (SeaPlaque GTG™; FMC, Rockland, ME, USA) gel in TAE buffer. The BMP-7 PCR product was excised from the gel and purified using a spin column containing a silica gel membrane (QIAquick™ Gel Extraction Kit; Qiagen, Inc., Valencia, CA, USA) as per kit instructions. The BMP-7 product was then digested with FseI and AscI enzymes. The cDNA was isolated on a 1% low melt agarose gel, and was then excised from the gel. The gel slice was melted at 70°C, extracted twice with an equal volume of Tris-buffered phenol, and EtOH precipitated. The DNA was resuspended in 10µl H₂O.

The BMP-7 cDNA was cloned into the FseI-AscI sites of a pAdTrack CMV plasmid (He *et al.*, Proc. Natl. Acad. Sci. USA, 1998, 95: 2509-2514). This construct contained further a green fluorescent protein (GFP) marker gene, a CMV promoter and a SV40 polyadenylation signal. In order to linearize the plasmid, approximately 5 µg of the plasmid was digested with PmeI enzyme. Approximately 1 µg of the linearized plasmid was cotransformed with 200 ng of supercoiled pAdEasy (He *et al.*, *supra*) into BJ5183 bacterial cells. The co-transformation was done using a Bio-Rad Gene Pulser at 2.5kV, 200 ohms and 25 µF. The entire co-transformation was plated on 4 LB plates containing 25 µg/ml kanamycin. The smallest colonies were picked and expanded in LB/kanamycin, and recombinant adenovirus DNA was identified by standard DNA miniprep procedures. Digestion of the recombinant adenovirus DNA with FseI and AscI confirmed the presence of BMP-7 DNA. The recombinant adenovirus miniprep DNA was transformed into *E. coli* DH10B competent cells (Life Technologies, Inc., Gaithersburg, MD, USA), and DNA was prepared therefrom.

Approximately 5 µg of recombinant adenoviral DNA was digested with PacI enzyme (New England Biolabs) for 3 hours at 37°C in a reaction volume of 100 µl containing 20-30U of PacI. The digested DNA was extracted twice with an equal volume of phenol/chloroform and precipitated with ethanol. The DNA pellet was resuspended in 10 µl distilled water. A T25 flask of QBI-293A cells (Quantum Biotechnologies, Inc., Montreal, Canada), inoculated the day before and grown to 60-70% confluence, were transfected with the PacI digested DNA. The PacI-digested DNA was diluted up to a total volume of 50 µl with sterile HBS (150 mM NaCl, 20 mM HEPES). In a separate tube, 20 µl of 1mg/ml N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methylsulfate (DOTAP; Boehringer Mannheim) was diluted to a total volume of 100 µl with HBS. The DNA was added to the DOTAP, mixed gently by pipeting up and down, and left at room temperature for 15 minutes.

The media was removed from the 293A cells and washed with 5 ml serum-free MEM-alpha (Life Technologies, Gaithersburg, MD, USA) containing 1 mM sodium pyruvate (Life Technologies), 0.1 mM MEM non-essential amino acids (Life Technologies) and 25 mM HEPES buffer (Life Technologies). 5 ml of serum-free MEM was added, and the cells were held at 37°C. The DNA/lipid mixture was added drop-wise to the flask, mixed gently, and incubated at 37°C for 4 hours. After 4 hours the media containing the DNA/lipid mixture was aspirated off and replaced with 5 ml complete MEM containing 5% fetal bovine serum. The transfected cells were monitored for GFP expression and formation of foci (viral plaques).

Seven days after transfection of 293A cells with the recombinant adenoviral DNA, cells expressing GFP started to form foci. The crude viral lysate was collected with a cell scraper to collect the cells. The lysate was transferred to a 50 ml conical tube. To release most of the virus particles from the cells, three freeze/thaw cycles were done in a dry ice/ethanol bath and a 37°C waterbath.

Ten 10-cm plates of nearly confluent (80-90%) 293A cells were set up 20 hours prior to infection. The crude lysate was amplified (primary amplification) to obtain a working stock of BMP-7 recombinant Ad5 virus (rAd5 virus) lysate. 200 ml of crude rAd5 virus lysate was added to each 10-cm plate, and the plates were monitored for 48 to 72 hours looking for cytopathic effects (CPE) under the white light microscope and expression of GFP under the fluorescent microscope. When all of the cells showed CPE, this first stock lysate was collected, and freeze/thaw cycles were performed as described above.

Secondary (2nd) amplification of BMP-7 rAd5 virus was obtained from twenty 15-cm tissue culture dishes of 80-90% confluent 293A cells. All but 20 ml of 5% MEM media was removed, and each dish was inoculated with 300-500 ml of first amplified rAd5 virus lysate. After 48 hours the cells were lysed from virus production, the lysate was collected into 250 ml polypropylene centrifuge bottles, and the rAd5 virus was purified.

NP-40 detergent was added to a final concentration of 0.5% to the bottles of crude lysate to lyse all cells. Bottles were placed on a rotating platform for 10 minutes and agitated as fast as possible. The debris was pelleted by centrifugation at 20,000 X G for 15 minutes. The supernatant was transferred to 250-ml polycarbonate centrifuge bottles, and 0.5 volume of 20% PEG8000/2.5M NaCl solution was added. The bottles were shaken overnight on ice. The bottles were centrifuged at 20,000 X G for 15 minutes, and the supernatants were discarded into a bleach solution. A white precipitate (precipitated virus/PEG) formed in two vertical lines along the walls of the bottles on either side of the spin mark. Using a sterile cell scraper, the precipitate from 2 bottles was resuspended in 2.5 ml PBS. The virus solution was

placed in 2-ml microcentrifuge tubes and centrifuged at 14,000 X G in a microcentrifuge for 10 minutes to remove any additional cell debris. The supernatants from the 2-ml microcentrifuge tubes were transferred into a 15-ml polypropylene snapcap tube and adjusted to a density of 1.34 g/ml with CsCl. The volume of the virus solution was estimated, and 0.55 g/ml of CsCl added. The CsCl was dissolved, and 1 ml of this solution weighed. The solution was transferred to polycarbonate, thick-walled, 3.2 ml centrifuge tubes (Beckman) and spun at 348,000 X G for 3-4 hours at 25°C. The virus formed a white band. Using wide-bore pipette tips, the virus band was collected.

The virus recovered from the gradient included a large amount of CsCl, which must be removed before it can be used on cells. Pharmacia PD-10 columns prepacked with Sephadex® G-25M (Pharmacia) were used to desalt the virus preparation. The column was equilibrated with 20 ml of PBS. The virus was loaded and allowed to run into the column. 5 ml of PBS was added to the column, and fractions of 8-10 drops collected. The optical density of a 1:50 dilution of each fraction was determined at 260 nm on a spectrophotometer, and a clear absorbance peak was identified. Peak fractions were pooled, and the optical density (OD) of a 1:25 dilution was determined. OD was converted into virus concentration using the formula $(\text{OD at } 260\text{nm})(25)(1.1 \times 10^{12}) = \text{virions/ml}$.

To store the virus, glycerol was added to the purified virus to a final concentration of 15%, mixed gently and stored in aliquots at -80°C.

Example 3: Construction of the Ad5 adenovirus vector having human BMP-7 insert.

The nucleic acid and amino acid sequences of the human BMP-7 are available on GenBank database under the accession number AL122058.

The codon-optimized human BMP-7 open reading frame (“ORF”) consists of 1296 bp (SEQ ID NO: 14) and encodes a 431 amino acids polypeptide (SEQ ID NO: 15).

To prepare adenovirus vectors according to the method described in the Example 2, the codon-optimized nucleotide sequence SEQ ID NO: 14 of the human BMP-7 polypeptide is used as starting material.

The recombinant Ad5 viruses, comprising as insert the codon-optimized nucleotide sequence of human BMP-7, are harvested, purified and stored as described in Example 2.

Example 4: Construction of the Ad5 adenovirus vector having canine BMP-7 insert.

The nucleic acid and amino acid sequences of the canine BMP-7 are available on GenBank database under the accession number XM_862341.

The codon-optimized canine BMP-7 open reading frame (“ORF”) consists of 1296 bp (SEQ ID NO: 2) and encodes a 431 amino acids polypeptide (SEQ ID NO: 3).

To prepare adenovirus vectors according to the method described in the Example 2, the codon-optimized nucleotide sequence SEQ ID NO: 2 of the canine BMP-7 polypeptide is used as starting material.

The recombinant Ad5 viruses, comprising as insert the codon-optimized nucleotide sequence of canine BMP-7, are harvested, purified and stored as described in Example 2.

Example 5: Construction of the Ad5 adenovirus vector having feline BMP-7 insert.

The nucleic acid and amino acid sequences of the feline BMP-7 are those described in Example 1.

The codon-optimized feline BMP-7 open reading frame ("ORF") consists of 1296 bp (SEQ ID NO: 18) and encodes a 431 amino acids polypeptide (SEQ ID NO: 19).

To prepare adenovirus vectors according to the method described in the Example 2, the codon-optimized nucleotide sequence SEQ ID NO: 18 of the feline BMP-7 polypeptide is used as starting material (pPB770 plasmid of the Example 1).

The recombinant Ad5 viruses, comprising as insert the codon-optimized nucleotide sequence of feline BMP-7, are harvested, purified and stored as described in Example 2.

Example 6: Construction of the Ad5 adenovirus vector having equine BMP-7 insert.

The nucleic acid and amino acid sequences of the equine BMP-7 are available on GenBank database under the accession number XM_001489796.

The equine BMP-7 open reading frame ("ORF") consists of 1296 bp (SEQ ID NO: 10) and encodes a 431 amino acids polypeptide (SEQ ID NO: 16).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 10 of the equine BMP-7 polypeptide is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of equine BMP-7, are harvested, purified and stored as described in Example 2.

Example 7: Construction of the CAV-2 adenovirus vector having canine BMP-7 insert.

Madin and Darby canine kidney (MDCK) cell suspensions are seeded in MEM supplemented with 7.5% fetal bovine serum, sodium pyruvate (1 mM final), glutamine (2 mM final), penicillin (50 U/ml), streptomycin (50 mg/ml) and non essential amino acids (0.1 mM final). Confluent cells are infected with serial dilutions of a CAV2 vaccine strain (US-A-6.090.393; US-A-6.156.567) and cultured under a 0.6% agarose overlay. CAV2 is subjected to several rounds of plaque purification.

In order to identify a DNA fragment containing the entire E3 region, purified CAV2 DNA aliquots are digested with *Bam*HI, *Bgl*II, *Hind*II, *Hind*III and *Pst*I and analyzed by

Southern blotting as described in Sambrook J. et al., Molecular cloning: a laboratory manual, 2nd edition Cold Spring Harbor, NY: Cold Spring Laboratory, 1989. Couples of primers LF189 SEQ ID NO: 29 (21 mer) 5'-TCAGTCATAGCCATCGACAGA-3'/LF190 SEQ ID NO: 30 (21 mer) (5'-GTGCTGGCTGGCACGGGCATT-3') and LF191 SEQ ID NO: 31 (21 mer) (5'-ATGTCCACCAAAGTCCCCTCT-3')/LF192 SEQ ID NO: 32 (21 mer) (5'-CCCGGGGCGTCGTATGGATAT-3') are designed to generate molecular probes specific of the 3' end of the CAV2 PVIII sequence or of the 5' end of the CAV2 fiber gene, respectively. The *HindIII* fragment A (4.0 Kbp), corresponding to the largest isolated restriction fragment recognized by both PVIII and Fiber probes is cloned into the vector pBluescript SK+ (Stratagene), generating pLF027. Sequencing of the entire pLF027 E3 insert is performed on both strands.

In order to facilitate subsequent cloning strategies, a DNA linker (SEQ ID NO: 33) (24 mer) 5'-GATACGCGTTCCATTAGCAGATCT-3', containing unique *BglII* and *MluI* restriction sites, is introduced into the CAV2 E3 region by a double round PCR amplification procedure. Initial PCR amplifications is performed using pLF027 DNA as template and the following primer couples [LF327 SEQ ID NO: 34 (24 mer) 5'-GGACACCTTTCTGATCAGTTCATT-3'/LF324 SEQ ID NO: 35 (45 mer) 5'-GATACGCGTTCCATTAGCAGATCTTTGAGGGGCCTGGAAATAGGC-3'] and [LF326 SEQ ID NO: 36 (24 mer) 5'-GGTTGTGTGGAAGACCCGGGGGCG-3'/LF325 SEQ ID NO: 37 (45 mer) 5'-AGATCTGCTAATGGAACGCGTATCGCTGCCCCCACAGTACAGCAA-3'], to generate two partially overlapping DNA fragments of 838 bp and 956 bp, respectively. The second round of PCR amplification is performed in the presence of both partially overlapping purified DNA fragments and both external primers LF327 and LF326. The purified 890 bp *PstI/AatII* fragment is ligated with the 6069 bp *PstI/AatII* DNA fragment of pLF027, generating pLF047A. In order to delete part of the CAV2 E3 region, a 428 bp deletion is engineered downstream (3') of the pLF047A *MluI* site. A 537 bp DNA fragment is generated by PCR using the pLF027 template and the primers pair LF361 SEQ ID NO: 38 (38 mer) 5'-CTAGTCATCTTAACGCGTGTCTCAACATCACCCGCGA-3'/LF334 SEQ ID NO: 39 (21 mer) 5'-CTTGCTTGTTATTAAAAAAG-3'. The purified 551 bp *MluI/AatII* DNA fragment is ligated with the 6944 bp *MluI/AatII* DNA fragment of pLF047A, generating pLF086. In order to engineer a larger deletion within the E3 region, a PCR amplification is implemented using pLF027 DNA as a template and primers LF437 SEQ ID NO: 40 (33 mer) 5'-ATCTTAACGCGTCCCTCAGCCTTCTAATGGGAC-3' and LF334.

The 287 bp *MluI/SmaI* amplified DNA fragment is ligated with the 6079 bp *MluI/SmaI* DNA fragment of pLF086, generating pLF095.

With the objective to reduce as much as possible the size of the expression cassette, a truncated hCMV IE promoter is generated by PCR using hCMV DNA as a template and

5 primers LF172 SEQ ID NO: 41 (31 mer) 5'-

ATCGTAAAGCTTAATGTCGTAATAACCCCGC-3' and LF159 SEQ ID NO: 42 (32 mer)

5'-TCTACTGCAGCCGGTGTCTTCTATGGAGGTCA-3'. The purified *HindIII/PstI* 166 bp

DNA fragment is cloned into the corresponding sites of the pCAT basic vector (Promega) to

generate pLF022. To further reduce the size of the polyadenylation cassette, a 170 bp DNA

10 fragment is amplified by PCR using primers LF377 SEQ ID NO: 43 (24 mer) 5'-

TCTTCGCCCCCGTTTTTCACCATGG-3' and LF378 SEQ ID NO: 44 (34 mer) 5'-

ATCACGCCGCGGCTTAAAAAATTACGCCCCGCC-3' and pLF022 DNA as template.

The purified DNA fragment is Klenow-treated and digested with *NcoI* before being ligated

with the 3655 bp *NcoI/BsaBI* DNA fragment of pLF022, generating pLF062. In order to

15 improve the expression of the recombinant antigen after the onset of CAV2 replication, the

human adenovirus 2 (hAd2) tripartite leader (TPL) is introduced downstream of the hCMV

IE promoter in pLF062. Oligonucleotides SPH6Etr1 SEQ ID NO: 45 (71 mer) 5'-

AATTCGGTACCAAGCTTCTTTATTCTATACTTAAAAAGTGAAAATAAATACAAAG

GTTCTTGACTCTCTTC-3', SPH6Etr2 SEQ ID NO: 46 (70 mer) 5'-

20 CGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTT

CGCGGTCTTTCCAGT-3', SPH6Etr3 SEQ ID NO: 47 (70 mer) 5'-

ACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCT

GAGCGAGTCCGCATC-3', SPH6Etr4 SEQ ID NO: 48 (60 mer) 5'-

GACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGC

25 CCGGGT-3', SPH6Etr5 SEQ ID NO: 49 (51 mer) 5'-

CTTTGTATTTATTTTCACTTTTAAAGTATAGAATAAAGAAGCTTGGTACCG-3',

SPH6Etr6 SEQ ID NO: 50 (72 mer) 5'-

GAAGAGTTTGTCTCAACCGCGAGCCCAACAGCTGGCCCTCGCAGACAGCGATG

CGGAAGAGAGTCAAGAAC-3', SPH6Etr7 SEQ ID NO: 51 (73 mer) 5'-

30 GCTCAGGTCCCTCGGTGGCGGAGTACGTTTCGGAGGCCGACGGGTTTCCGATCCAA

GAGTACTGGAAAGACCGC-3', and SPH6Etr8 SEQ ID NO: 52 (75 mer) 5'-

CTAGACCCGGGCTTGCGACTGTGACTGGTTAGACGCCTTTCTCGAGAGGTTTTCC

GATCCGGTCGATGCGGACTC-3' are kinased and annealed and the 271 bp product was

gel purified. A 220 bp DNA fragment containing the entire hAd2 TPL flanked by *PstI* and

XbaI restriction sites is generated by PCR using primers LF394 SEQ ID NO: 53 (36 mer) 5'-ATCGTCCTGCAGACTCTCTTCCGCATCGCTGTCTGC-3' and LF395 SEQ ID NO: 54 (29 mer) 5'-GCTCTAGACTTGCGACTGTGACTGGTTAG-3' and the aforementioned gel purified annealed oligonucleotides as template, is subsequently ligated with the 3800 bp

5 *PstI/XbaI* pLF062 fragment, to generate pLF066. In order to further reduce the size of the expression cassette, the 3936 bp *SacI/PstI* fragment of pLF066 is ligated with annealed oligonucleotides LF397 SEQ ID NO: 55 (20 mer) 5'-CGTTTAGTGAACCGTCTGCA-3' and LF398 SEQ ID NO: 56 (20 mer) 5'-GACGGTTCATAAACGAGCT-3', to generate pLF069 in which the 5'UTR of the hCMV IE promoter is replaced by the hAd2TPL.

10 To increased expression canine BMP-7, a codon-optimized cDNA sequence is chemically synthesized based on Genbank sequence P34819 and subsequently subcloned into pLF069 to generate pLF1000. The pLF1000 plasmid contains the codon-optimized canine BMP-7 cDNA in the rightward orientation in the pLF069 backbone. To further reduce the size of the polyadenylation cassette, a 160 bp DNA fragment is amplified using primers

15 M13R SEQ ID NO: 57 (18 mer) 5'-GTAAAAACGACGGCCAGT-3' and LF409 SEQ ID NO: 58 (33 mer) 5'-ATCGTCCCGCGGAATTGTTGTTGTTAACTTGTT-3' and pCAT Basic DNA as template. The amplified 145 bp *KspI/BamHI* DNA fragment is ligated with the 5002 bp *KspI/BamHI* DNA fragment of pLF1000, generating pLF1001, which contains the codon-optimized canine BMP7 cDNA flanked by a shorter polyadenylation cassette.

20 5 µg of the purified CAV2 DNA are transfected into MDCK cells using Lipofectamine as described by the manufacturer (Gibco Lifesciences). After 24 hours of incubation at 37°C, the serum free medium is removed and replaced by the supplemented MEM medium. The culture is incubated at 37°C for 8 days with supplemented MEM medium being added to it on the third day. No cytopathic effect (CPE) could be evidenced during this

25 incubation. On day 8 the transfected MDCK cells are harvested. After sonication on ice, 2 ml of the transfected culture are used to infect a confluent MDCK monolayer. Plaques appear after 5 days with a typical yield of at least 2,000 pfu/10 µg of purified DNA.

The pLF1001 DNA fragment containing the canine BMP-7 cDNA in the rightward orientation flanked by the aforementioned expression regulatory sequences is purified by

30 GeneClean and resuspended to a concentration of 10 ng/ml and subsequently, recombined *in vitro* with purified CAV2 DNA in the presence of Lipofectamine as described by the manufacturer.

The CAV2 DNA/liposome complexes are gently mixed with supplemented MEM medium (serum free) before being transfected into MDCK cells as described above. Plaques

are screened for recombinant viruses by the filter hybridization method. Briefly, plaques were transferred onto a nitrocellulose filter, then transferred from the original filters to replica filters. The original filters are hybridized with a specific DNA probe to identify plaques containing the canine BMP-7 gene. Recombinant virus is retrieved from the corresponding
5 plaques on the replica filter.

Example 8: Animal experiment and results.

A study was conducted in sheep to demonstrate the ability of BMP-7 gene therapy to interfere with the progression of post-traumatic osteoarthritis.

14 adult, 1.5-5.0 year old, 40-70 kg, castrated male or non-gravid female Arcott sheep
10 were allocated randomly into 2 groups (Group 1 and Group 2).

Under general anesthesia and using aseptic technique, all sheep received standardized 30 MPa impact injuries to both (left and right) medial femoral condyles by a 3 cm minimally invasive arthrotomy. Briefly, a 2 cm long infrapatellar arthrotomy and partial resection of the fat pad was used to expose the medial femoral condyle of both knee joints. Using a hand-held
15 spring loaded impact device equipped with an 6 mm diameter tip and an in line force transducer, two overlapping 30 MPa impact injuries were made 1 cm distal to the linea terminalis. It was day 0 (D0) of the study.

At D7, the sheep were sedated with diazepam (10 mg/kg) and ketamine (3-5 mg/kg) to allow the following treatments to be administered. The sheep of Group 1 received a dose
20 of 1 mL of murine BMP-7 Ad5 vector (example 2) (10^9 virus particles/mL) into the stifle joint of one knee. The administration was done intra-articularly with a syringe and needle into the femoropatellar joint with the animal sedated and held upright with the limb extended. Injection was done after synovial fluid (1 mL) was collected. The other knee was not treated. FIG. 1 gives information about the treatment administered on each knee of each animals of
25 Group 1. The sheep of Group 2 did not receive any treatment and remained as control.

Serum and synovial fluid were harvested on D0, D14, D21, D28, D60 and D90. On D90, tissues were also collected for macroscopic examination and histology.

Stall side clinical signs were recorded once daily during the experiment period. Lameness was recorded daily on a scale from 0-5 where 0 is normal and 5 is non-weight
30 bearing. Animals with a score of $> 2/5$ for more than 7 days will be examined and an arthrocentesis performed to rule out sepsis. Animals with a score of $> 3/5$ for 7 days will be administered analgesics (fentanyl patch 1 mg/kg 5 days) until the lameness improves or the animal is removed from the study.

One animal of Group 1 was euthanized during experiment due to septicemia and pneumonia.

FIG. 1 provides macroscopic data at necropsy on D90. This figure shows the beneficial effect of the treatment, demonstrated using macroscopic endpoint ($p < 0.05$).

5 FIG. 2 provides pictures of the left and right knee of one of the animals of Group 1, Y13.

FIG. 3 provides quantitative macroscopic observations and shows a clear improvement in cartilage damage between treated and control animals ($p < 0.001$). Macroscopic indicators of cartilage preservation after injury included reduction in surface roughening as measured by India ink retention. Briefly, the area of abnormal cartilage was delineated using India ink staining. Stained areas were calculated by tracing ink uptake onto plastic film and area measurement with semi-automated morphometry software (Northern Eclipse™).

15 FIG. 4 provides quantitative histological observations using OARSI scoring with assigning a grade to the depth of cartilage erosion and a stage to the India ink stained area (about OARSI score see Pritzker KPH *et al.*, Osteoarthritis and Cartilage, 2006, 14: 13-29). In a linear model statistical analysis, treated Group 1 joints were improved over Group 2 controls ($p < 0.0007$) and Group 1 contralateral joints ($p < 0.004$).

20 Reduced disease progression in treated joints compared to contralateral joints and to the joints of control animals were supported by the absence of collagen degradation CII3/4 short epitope (hallmarks of cartilage degradation and OA progression) at distant sites from the experiment defect;

- 7 out of 8 control (group 2) joints had evidence of progressive degeneration as indicated by the presence of CII3/4 short epitope.
- 25 – 3 out of 4 (examined) contralateral joints had CII3/4 short staining distant from the injury site.
- 0 out of 7 Ad5 BMP-7 treated knee joints had evidence of C3/4 short epitope staining distant from the injury site.

30 Reduced disease progression in treated joints were also supported by TUNEL staining (to determine if treatment blocked programmed cell death after mechanical injury to cartilage; about TUNEL staining see Echigo R. *et al.*, J. Vet. Med. Sci., 2006, 68(8): 899-902):

- Of the 7 Ad5 BMP-7 treated joints, 7 were positive at the injury site, 2 were negative in the surrounding cartilage and the remaining 5 had reduced TUNEL staining distant from the experimental impact zone.
- All contralateral joints had TUNEL positivity both in the defect sites and in the surrounding cartilage.
- All controls had TUNEL positivity both in the defect sites and in the surrounding cartilage.

Evidence of improvement in Ad5 BMP-7 transfected joints over contralateral joint has been obtained with a lack of OA progression and cell loss indicating reduced disease progression in treated joints. This data clearly demonstrates the beneficial effect of BMP-7 adenovirus-based gene therapy in a very severe experimental model of osteoarthritis.

Example 9: Construction of the Ad5 adenovirus vector having equine IL10 insert.

The nucleic acid and amino acid sequences of the equine interleukine-10 (IL10) are available on GenBank database under the accession number U38200.

The equine IL10 open reading frame (“ORF”) consists of 537 bp (SEQ ID NO: 59) and encodes a 178 amino acids polypeptide (SEQ ID NO: 60).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 59 is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of equine IL10, are harvested, purified and stored as described in Example 2.

Example 10: Construction of the Ad5 adenovirus vector having canine IL10 insert.

The nucleic acid and amino acid sequences of the canine interleukine-10 (IL10) are available on GenBank database under the accession number XM_850467.1.

The canine IL10 ORF consists of 540 bp (SEQ ID NO: 61) and encodes a 179 amino acids polypeptide (SEQ ID NO: 62).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 61 is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of canine IL10, are harvested, purified and stored as described in Example 2.

Example 11: Construction of the Ad5 adenovirus vector having feline IL10 insert.

The nucleic acid and amino acid sequences of the feline interleukine-10 (IL10) are available on GenBank database under the accession number NM_001009209.1.

The feline IL10 ORF consists of 537 bp (SEQ ID NO: 63) and encodes a 178

amino acids polypeptide (SEQ ID NO: 64).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 63 is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of feline IL10, are harvested, purified and stored as described in Example 2.

Example 12: Construction of the Ad5 adenovirus vector having human IL10 insert.

The nucleic acid and amino acid sequences of the human interleukine-10 (IL10) are available on GenBank database under the accession number NM_000572.2.

The human IL10 ORF consists of 537 bp (SEQ ID NO: 65) and encodes a 178 amino acids polypeptide (SEQ ID NO: 66).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 65 is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of human IL10, are harvested, purified and stored as described in Example 2.

Example 13: Construction of the Ad5 adenovirus vector having viral IL10 insert.

The nucleic acid and amino acid sequences of the viral interleukine-10 (IL10) are available on GenBank database under the accession number AF182315.

The viral IL10 ORF consists of 528 bp (SEQ ID NO: 67) and encodes a 175 amino acids polypeptide (SEQ ID NO: 68).

To prepare adenovirus vectors according to the method described in the Example 2, the nucleotide sequence SEQ ID NO: 67 is used as starting material.

The recombinant Ad5 viruses, comprising as insert the nucleotide sequence of viral IL10, are harvested, purified and stored as described in Example 2.

The invention is further described by the following numbered paragraphs:

1. A method of treating a mammalian subject suffering from osteoarthritis, comprising, administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle and recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter, wherein the BMP-7 polypeptide is expressed in vivo in the mammalian subject.

2. The method according to paragraph 1, wherein the recombinant adenovirus vectors are human adenoviruses.

3. The method according to paragraph 2, wherein the human adenoviruses are human adenoviruses type 5 (hAd5).

4. The method according to paragraph 3, wherein the human adenoviruses type 5 (hAd5) are PEGylated.

5. The method according to paragraph 1, wherein the recombinant adenovirus vectors are canine adenoviruses.

5 6. The method according to paragraph 5, wherein the canine adenoviruses are canine adenoviruses type 2 (CAV2).

7. The method according to paragraph 1, wherein the mammalian subject is selected from the group consisting of human, canidae, equidae and felidae.

8. The method according to paragraph 1 wherein the mammalian subject is a dog, a
10 bitch or a puppy.

9. The method according to paragraph 1 wherein the mammalian subject is a cat or a kitten.

10. The method according to paragraph 1 wherein the mammalian subject is a horse, a mare or a foal.

15 11. The method according to paragraph 1, wherein the BMP-7 polypeptide is selected from the group consisting of a pre-pro BMP-7 polypeptide, a pro-BMP-7 polypeptide, and a mature BMP-7 polypeptide.

12. The method according to paragraph 1, wherein the BMP-7 polypeptide is selected from the group consisting of a canine pre-pro BMP-7 polypeptide, a canine pro-BMP-7
20 polypeptide, a canine mature BMP-7 polypeptide, a feline pre-pro BMP-7 polypeptide, a feline pro-BMP-7 polypeptide, a feline mature BMP-7 polypeptide, an equine pre-pro BMP-7 polypeptide, an equine pro-BMP-7 polypeptide, an equine mature BMP-7 polypeptide, a human pre-pro BMP-7 polypeptide, a human pro-BMP-7 polypeptide, and a human mature BMP-7 polypeptide.

25 13. The method according to paragraph 1, wherein the nucleic acid sequence encoding the BMP-7 polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 18, and fragments, variants, derivatives and homologs thereof that encode polypeptides having BMP-7 activity.

30 14. The method according to paragraph 1, wherein the BMP-7 polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 and fragments, variants, derivatives and homologs thereof having BMP-7 activity.

15. The method according to paragraph 1, wherein the BMP-7 polypeptide comprises a signal peptide.

16. The method according to paragraph 15, wherein the signal peptide is selected from the group consisting of the BMP-7 signal sequence, the IGF-1 signal sequence, and the tPA signal sequence.

17. The method according to paragraph 15, wherein the signal peptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, and fragments, variants, derivatives and homologs thereof that encode peptides having signal peptide activity.

18. The method according to paragraph 15, wherein the signal peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 12, and fragments, variants, derivatives and homologs thereof having signal peptide activity.

19. The method according to paragraph 1 wherein the promoter is selected from the group consisting of a CMV IE promoter, a RSV promoter, an HSV-1 TK promoter, a SV40 early promoter, a SV40 late promoter, an adenovirus major late promoter, a phosphoglycerate kinase gene promoter, a metallothionein gene promoter, an α -1 antitrypsin gene promoter, an albumin gene promoter, a collagenase gene promoter, an elastase I gene promoter, a β -actin gene promoter, a β -globin gene promoter, a γ -globin gene promoter, an α -fetoprotein gene promoter, and a muscle creatin kinase gene promoter.

20. The method according to paragraph 1 wherein the BMP-7 polypeptide is selected from the group consisting of a canine pre-pro BMP-7 polypeptide, a canine pro-BMP-7 polypeptide, a canine mature BMP-7 polypeptide and the promoter is a canine synoviocyte specific promoter.

21. The method according to paragraph 1 wherein the nucleic acid sequence encoding the BMP-7 polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and fragments, variants, derivatives and homologs thereof that encode polypeptides having BMP-7 activity and the promoter is a canine synoviocyte specific promoter.

22. A pharmaceutical composition comprising recombinant adenovirus vectors according to anyone of paragraphs 1 to 21, and at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle.

* * *

Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to

51440-134

particular details set forth in the above description as many apparent variations thereof are possible without departing from the scope of the present invention, which is as defined by the appended claims.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 51440-134 Seq 25-MAR-10 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> FISCHER, LAURENT BERNARD

<120> ARTICULAR CARTILAGE GENE THERAPY WITH RECOMBINANT VECTOR ENCODING BMP-7

<130> MER 07-101

<140> PCT/US2008/079090

<141> 2008-10-07

<160> 68

<170> PatentIn version 3.3

<210> 1

<211> 1296

<212> DNA

<213> Canis sp.

<400> 1

atgcacgtgc	gctcgccctg	cgccgcggcg	ccccgcagct	tcgtggcgct	ctgggcgccc	60
ctgctcctgc	tgcgtccgc	cctggccgac	ttcagcctgg	acaacgaggt	gcactcgagc	120
ttcatccacc	ggcgccctccg	cagccaggag	cggcgggaga	tgcagcgcca	gatcctctct	180
atcctgggct	tgccccaccg	cccgcgcccg	cacctccagg	gcaagcacia	ctcggcgccc	240
atgttcatgc	tggacctgta	caatgccatg	gcggtggagg	agggcgggcg	gcccgcgggc	300
cagggcttct	cctacccta	caaggccgtc	ttcagcacc	agggccccc	tctggccagc	360
ctgcaagaca	gccacttcct	caccgacgcc	gacatggtca	tgagcttcgt	caacctcgtg	420
gagcatgaca	aagagttctt	ctatccacgt	taccaccacc	gggagttccg	gttcgatctc	480
tccaagatcc	cagaggggga	agctgtgact	gcagccgaat	tccggatcta	caaggactac	540
attcgggagc	gcttcgacaa	cgagacgttc	cggatcagcg	tttaccaggt	gctgcaggag	600
cacttgggca	gggagtcaga	cctgttcctg	ctggacagcc	gcaccctctg	ggcctcggag	660
gagggctggc	tgggtgttca	catcacagcc	accagcaacc	actgggtggt	caaccacga	720
cacaacctgg	gcctgcagct	ctgcgtggag	accttggaag	ggcagagcat	caaccccaag	780
ttggcgggcc	tgatcggggc	gcacggggcc	cagaacaagc	agcccttcat	ggtggccttc	840
ttcaaggcca	cgaagtcca	cctccgcagc	acgcgtcca	cgggcgcca	gcagcgagc	900
cagaaccgct	ccaagacgcc	caagaaccag	gaagccctgc	gggtggcca	cgtcgcagaa	960

```

aacagcagca gcgaccagag gcaggcctgc aagaagcacg aactgtacgt cagcttccgc 1020
gatctgggct ggcaggactg gatcatcgct cccgaaggct atgccgctta ctactgtgag 1080
ggggagtgtg ccttccccct gaactcctac atgaacgcc acaaccacgc catcgtgcag 1140
acgctgggtcc acttcatcaa ccccgaaacg gtgcccaagc catgctgtgc cccactcag 1200
ctcaacgcc a tctctgtcct ctacttcgac gacagctcca acgtcatcct gaagaaatac 1260
agaaacatgg tcgtccgagc ctgtggctgc cactag 1296

```

<210> 2
 <211> 1296
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 construct

```

<400> 2
atgcatgtgc gcagcccgtg cgcggcggcg ccgcgcagct ttgtggcgct gtgggcgcgcg 60
ctgctgctgc tgcgcagcgc gctggcggat tttagcctgg ataacgaagt gcatagcagc 120
tttattcatc gccgcctgcg cagccaggaa cgccgcgaaa tgcagcgcga aattctgagc 180
attctggggcc tgcgcgcatcg cccgcgcccg catctgcagg gcaaacataa cagcgcgcgcg 240
atgttttatgc tggatctgta taacgcgatg gcggtggaag aaggcggcgg cccggatggc 300
cagggcttta gctatccgta taaagcgggt tttagcacc agggcccgcg gctggcgagc 360
ctgcaggata gccattttct gaccgatgcg gatatgggtga tgagctttgt gaacctggtg 420
gaacatgata aagaatTTTT ttatccgcgc tatcatcatc gcgaatttcg ctttgatctg 480
agcaaaattc cggaaggcga agcggtgacc gcggcggaat ttcgcattta taaagattat 540
attcgcgaac gctttgataa cgaaaccttt cgcattagcg tgtatcaggt gctgcaggaa 600
catctggggcc gcgaaagcga tctgtttctg ctggatagcc gcacctgtg ggcgagcgaa 660
gaaggctggc tgggtgtttga tattaccgcg accagcaacc attgggtggg gaaccgcgcg 720
cataacctgg gctgcagct gtgcgtggaa accctggatg gccagagcat taaccgaaa 780
ctggcggggcc tgattggccg ccatggcccg cagaacaaac agccgtttat ggtggcgttt 840
tttaaagcga ccgaagtgca tctgcgcagc accgcgagca ccggcgcgaa acagcgcagc 900
cagaaccgca gcaaaacccc gaaaaaccag gaagcgctgc gcgtggcgaa cgtggcggaa 960
aacagcagca gcgatcagcg ccaggcgtgc aaaaaacatg aactgtatgt gagctttcgc 1020
gatctgggct ggcaggattg gattattgcg ccggaaggct atgcggcgta ttattgcgaa 1080
ggcgaatgcg cgtttccgct gaacagctat atgaacgcga ccaaccatgc gattgtgcag 1140
accctgggtgc attttattaa cccggaaacc gtgccgaaac cgtgctgcgc gccgaccag 1200
ctgaacgcga ttagcgtgct gtattttgat gatagcagca acgtgattct gaaaaaatat 1260
cgcaacatgg tgggtgcgcgc gtgcggctgc cattaa 1296

```

<210> 3
 <211> 431
 <212> PRT
 <213> Canis sp.

```

<400> 3
Met His Val Arg Ser Pro Cys Ala Ala Ala Pro Arg Ser Phe Val Ala
1          5          10          15
Leu Trp Ala Pro Leu Leu Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
20          25          30
Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
35          40          45
Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
50          55          60
Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65          70          75          80
Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
85          90          95
Gly Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
100         105         110
Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
115         120         125

```

Asp	Ala	Asp	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys
130						135					140				
Glu	Phe	Phe	Tyr	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu
145					150					155					160
Ser	Lys	Ile	Pro	Glu	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile
				165					170					175	
Tyr	Lys	Asp	Tyr	Ile	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Arg	Ile
			180					185					190		
Ser	Val	Tyr	Gln	Val	Leu	Gln	Glu	His	Leu	Gly	Arg	Glu	Ser	Asp	Leu
		195				200					205				
Phe	Leu	Leu	Asp	Ser	Arg	Thr	Leu	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu
210						215					220				
Val	Phe	Asp	Ile	Thr	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg
225					230					235					240
His	Asn	Leu	Gly	Leu	Gln	Leu	Cys	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser
				245					250					255	
Ile	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn
			260					265					270		
Lys	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Leu
		275					280					285			
Arg	Ser	Thr	Arg	Ser	Thr	Gly	Ala	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser
290						295					300				
Lys	Thr	Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Val	Ala	Asn	Val	Ala	Glu
305					310					315					320
Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr
				325					330					335	
Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu
			340					345					350		
Gly	Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn
		355					360				365				
Ser	Tyr	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
370						375					380				
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
385					390					395					400
Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile
				405					410					415	
Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His	
			420					425					430		

<210> 4
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 4
 atggatgcaa tgaagagagg gctctgctgt gtgctgctgc tgtgtggagc agtcttcggt
 tcgcccagc

60
 69

<210> 5
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 5
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15
 Ala Val Phe Val Ser Pro Ser
 20

<210> 6
 <211> 84

<212> DNA

<213> Homo sapiens

<400> 6

atggatgcaa	tgaagagagg	gctctgctgt	gtgctgctgc	tgtgtggagc	agtcttcggt	60
tcgcccagcc	aggaaatcca	tgcc				84

<210> 7

<211> 28

<212> PRT

<213> Homo sapiens

<400> 7

Met	Asp	Ala	Met	Lys	Arg	Gly	Leu	Cys	Cys	Val	Leu	Leu	Leu	Cys	Gly
1				5				10						15	
Ala	Val	Phe	Val	Ser	Pro	Ser	Gln	Glu	Ile	His	Ala				
			20				25								

<210> 8

<211> 75

<212> DNA

<213> Equus sp.

<400> 8

atgcacatca	tgagcagcag	ccacctgttc	tacctggccc	tgtgcctgct	gaccttcacc	60
agcagcgcca	ccgcc					75

<210> 9

<211> 25

<212> PRT

<213> Equus sp.

<400> 9

Met	His	Ile	Met	Ser	Ser	Ser	His	Leu	Phe	Tyr	Leu	Ala	Leu	Cys	Leu
1				5				10						15	
Leu	Thr	Phe	Thr	Ser	Ser	Ala	Thr	Ala							
			20				25								

<210> 10

<211> 1296

<212> DNA

<213> Equus caballus

<400> 10

atgcacgtgc	gctcgctgcg	caccgcggcg	ccccacagct	ttgtggcgct	ctgggcgccc	60
ctgttcctgc	tgcgctccgc	cctggccgac	ttcagcctgg	acaacgaggt	gcactcgagc	120
ttcatccacc	ggcgctccg	cagccaggag	cggcgggaga	tgcagcgca	gatcctctcc	180
atcttgggtt	tgccccatcg	cccgcgcccc	cacctccagg	gcaagcacia	ctcggcgccc	240
atgttcatgc	tggacctgta	caatgccatg	gcggtggagg	agagcggcgg	gcccgcggc	300
cagggtctct	cctaccccca	caaggccgtc	tccagtaccc	agggccccc	tctggccagc	360
ctgcaagata	gccacttcct	caccgacgcc	gacatgggtca	tgagcttcgt	caaccttgtg	420
gaacacgaca	aagagttctt	tcacccgcgc	taccaccatc	gggagttccg	gtttgatctt	480
tccaagatcc	cagaagggga	ggccgtgact	gcggccgagt	tccggatcta	caaggattac	540
gtccgggagc	gcttcgataa	cgagacgttc	cgcacagcg	tgtaccaagt	gctgcaggag	600
cacctggcca	gggagtcgga	cctgttcctg	cttgacagcc	gcacctctg	ggcctcagag	660
gagggctggc	tgggtgttcga	catcacagcc	accagcaacc	actgggtggg	caaccacgg	720
cacaatctgg	gcctgcagct	ctcgggtggg	accttggacg	ggcagagcgt	gaaccccaag	780
ctggcgggcc	tgatcgggcg	gcacggcccc	cagaccaagc	agcctttcat	ggtcgccttc	840
ttcaaggcca	ccgaggtcca	ccttcgcagc	acccgctcca	cgggcggcaa	gcagcgcagc	900
cagaaccgct	ccaagacgcc	caagaaccag	gaggccctgc	gggtggccaa	tgtcgcagag	960

```

aacagcagca gcgaccagag gcaggcctgt aagaagcacg agctgtacgt cagcttccgc 1020
gacctgggct ggcaggactg gatcatcgca cccgaaggct atgccgccta ctactgcgag 1080
ggagagtgcg ccttcccgcg gaactcctac atgaacgcca ccaaccacgc catcgtgcag 1140
acactgggtcc acttcatcaa cccagagacg gtgcccaagc cttgctgtgc acccacgcag 1200
ctgaacgcca tctccgtcct ctactttgac gacagctcca acgtcatcct gaagaaatac 1260
agaaacatgg tcgtccgggc ctgtggctgc cactag 1296

```

<210> 11
 <211> 75
 <212> DNA
 <213> Canis sp.

```

<400> 11
atgcacaccg tgtcctcctc gcacctcttc tacctggcac tgtgcttgct caccttcccc 60
agccccgcca cagct 75

```

<210> 12
 <211> 25
 <212> PRT
 <213> Canis sp.

```

<400> 12
Met His Thr Val Ser Ser Ser His Leu Phe Tyr Leu Ala Leu Cys Leu
1          5          10          15
Leu Thr Phe Pro Ser Pro Ala Thr Ala
          20          25

```

<210> 13
 <211> 1296
 <212> DNA
 <213> Homo sapiens

```

<400> 13
atgcacgtgc gctcactgcg agctgcggcg ccgcacagct tcgtggcgct ctgggcaccc 60
ctgttcctgc tgcgctccgc cctggccgac ttcagcctgg acaacgaggt gcactcgagc 120
ttcatccacc ggcgcctccg cagccaggag cggcgggaga tgcagcgcgga gatcctctcc 180
atthtgggct tgccccaccg cccgcgcccg cacctccagg gcaagcaciaa ctcggcaccc 240
atgttcatgc tggacctgta caacgccatg gcggtggagg agggcgggcg gcccgggcggc 300
cagggcttct cctaccctta caaggccgtc ttcagtacct agggcccccc tctggccagc 360
ctgcaagata gccatttcct caccgacgcc gacatgggtca tgagcttcgt caacctcgtg 420
gaacatgaca aggaattctt ccaccacgc taccaccatc gagagtccg gtttgatctt 480
tccaagatcc cagaagggga agctgtcacg gcagccgaat tccggatcta caaggactac 540
atccgggaac gcttcgacaa tgagacgttc cggatcagcg tttatcaggt gctccaggag 600
cacttgggca gggaatcgga tctcttcctg ctcgacagcc gtaccctctg ggcctcggag 660
gagggctggc tgggtgttga catcacagcc accagcaacc actgggtggg caatccgcgg 720
cacaacctgg gcctgcagct ctcggtggag acgctggatg ggcagagcat caaccccaag 780
ttggcgggcc tgattgggcg gcacggggcc cagaacaagc agcccttcat ggtggctttc 840
ttcaaggcca cggaggtcca cttccgcagc atccggtcca cggggagcaa acagcgcagc 900
cagaaccgct ccaagacgcc caagaaccag gaagccctgc ggatggccaa cgtggcagag 960
aacagcagca gcgaccagag gcaggcctgt aagaagcacg agctgtatgt cagcttccga 1020
gacctgggct ggcaggactg gatcatcgcg cctgaaggct acgccgccta ctactgtgag 1080
ggggagtgtg ccttccctct gaactcctac atgaacgcca ccaaccacgc catcgtgcag 1140
acgctgggtcc acttcatcaa cccggaaacg gtgcccaagc cctgctgtgc gcccacgcag 1200
ctcaatgcca tctccgtcct ctacttcgat gacagctcca acgtcatcct gaagaaatac 1260
agaaacatgg tgggtccgggc ctgtggctgc cactag 1296

```

<210> 14
 <211> 1299
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
construct

<400> 14

atgcacgtgc	ggagcctgag	agccgctgcc	ccccacagct	tcgtggccct	gtgggcccct	60
ctgttcctgc	tgcggagcgc	cctggccgac	ttcagcctgg	acaacgaggt	gcacagcagc	120
ttcatccacc	ggcggctgcg	gagccaggaa	cggcgggaga	tgcagcggga	gacccctgagc	180
atcctggggc	tgcttcaccg	gcccaggcct	cacctgcagg	gcaagcacia	cagcgccccc	240
atgttcatgc	tggacctgta	caacgccatg	gccgtggagg	aaggcggcgg	acctggcggc	300
cagggcttca	gctaccccta	caaggccgtg	ttcagcacac	agggccctcc	tctggccagc	360
ctgcaggaca	gccacttcct	gaccgacgcc	gacatgggtg	tgagcttcgt	gaacctgggtg	420
gagcacgaca	aagagttcct	ccaccccaga	taccaccacc	gggagttccg	gttcgacctg	480
agcaagatcc	ccgagggcga	ggccgtgaca	gccgcccagt	tccggatcta	caaggactac	540
atccgggagc	ggttcgacaa	cgagaccttc	cggatcagcg	tgtaccaggt	gctgcaggaa	600
cacctggggc	gggagagcga	cctgtttctg	ctggacagcc	ggacactgtg	ggccagcagag	660
gaaggctggc	tggtgttcga	catcaccgcc	acctccaacc	actgggtggg	gaacccccgg	720
cacaatctgg	gcctgcagct	gtccgtggag	acctggagc	gccagagcat	caaccccaag	780
ctggccggcc	tgatcggcag	acacggcccc	cagaacaagc	agcccttcat	ggtggccttt	840
ttcaaggcca	ccgaggtgca	cttcagaagc	atccggtcca	ccggcagcaa	gcagcggagc	900
cagaacagaa	gcaagacccc	caagaaccag	gaagccctgc	ggatggccaa	cgtggccgag	960
aacagcagca	gcgaccagcg	gcaggcctgc	aagaagcacg	agctgtacgt	cagcttccgg	1020
gacctgggct	ggcaggactg	gatcatcgcc	cccgagggct	acgccgccta	ctactgcgag	1080
ggcgagtgcg	ccttccccct	gaacagctac	atgaacgcca	ccaaccacgc	catcgtgcag	1140
acctggtgc	actttatcaa	ccccgagacc	gtgcccaagc	cctgctgcgc	ccccaccag	1200
ctgaacgcca	tcagcgtgct	gtacttcgac	gacagcagca	acgtgatcct	gaagaaatac	1260
cggaacatgg	tggtgcgggc	ctgcggctgc	cactgataa			1299

<210> 15

<211> 431

<212> PRT

<213> Homo sapiens

<400> 15

Met	His	Val	Arg	Ser	Leu	Arg	Ala	Ala	Ala	Pro	His	Ser	Phe	Val	Ala	
1				5					10					15		
Leu	Trp	Ala	Pro	Leu	Phe	Leu	Leu	Arg	Ser	Ala	Leu	Ala	Asp	Phe	Ser	
			20					25					30			
Leu	Asp	Asn	Glu	Val	His	Ser	Ser	Phe	Ile	His	Arg	Arg	Leu	Arg	Ser	
		35					40					45				
Gln	Glu	Arg	Arg	Glu	Met	Gln	Arg	Glu	Ile	Leu	Ser	Ile	Leu	Gly	Leu	
	50					55					60					
Pro	His	Arg	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro	
65					70				75					80		
Met	Phe	Met	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Gly	Gly	
			85					90					95			
Gly	Pro	Gly	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	Tyr	Lys	Ala	Val	Phe	Ser	
		100					105					110				
Thr	Gln	Gly	Pro	Pro	Leu	Ala	Ser	Leu	Gln	Asp	Ser	His	Phe	Leu	Thr	
	115						120					125				
Asp	Ala	Asp	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys	
	130				135				140							
Glu	Phe	Phe	His	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu	
145				150					155					160		
Ser	Lys	Ile	Pro	Glu	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile	
		165					170					175				
Tyr	Lys	Asp	Tyr	Ile	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Arg	Ile	
	180						185					190				
Ser	Val	Tyr	Gln	Val	Leu	Gln	Glu	His	Leu	Gly	Arg	Glu	Ser	Asp	Leu	
	195					200					205					
Phe	Leu	Leu	Asp	Ser	Arg	Thr	Leu	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu	
	210					215					220					

Val	Phe	Asp	Ile	Thr	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg
225					230					235					240
His	Asn	Leu	Gly	Leu	Gln	Leu	Ser	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser
				245					250					255	
Ile	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn
			260					265					270		
Lys	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Phe
		275					280					285			
Arg	Ser	Ile	Arg	Ser	Thr	Gly	Ser	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser
	290					295					300				
Lys	Thr	Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala	Glu
305					310					315					320
Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr
				325					330					335	
Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu
			340					345					350		
Gly	Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn
		355					360					365			
Ser	Tyr	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
	370					375					380				
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
385					390					395					400
Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile
				405					410					415	
Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His	
			420					425					430		

<210> 16

<211> 431

<212> PRT

<213> Equus caballus

<400> 16

Met	His	Val	Arg	Ser	Leu	Arg	Thr	Ala	Ala	Pro	His	Ser	Phe	Val	Ala
1				5					10					15	
Leu	Trp	Ala	Pro	Leu	Phe	Leu	Leu	Arg	Ser	Ala	Leu	Ala	Asp	Phe	Ser
			20					25					30		
Leu	Asp	Asn	Glu	Val	His	Ser	Ser	Phe	Ile	His	Arg	Arg	Leu	Arg	Ser
		35					40					45			
Gln	Glu	Arg	Arg	Glu	Met	Gln	Arg	Glu	Ile	Leu	Ser	Ile	Leu	Gly	Leu
	50					55					60				
Pro	His	Arg	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro
65					70					75					80
Met	Phe	Met	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Ser	Gly
				85					90					95	
Gly	Pro	Asp	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	His	Lys	Ala	Val	Ser	Ser
			100					105						110	
Thr	Gln	Gly	Pro	Pro	Leu	Ala	Ser	Leu	Gln	Asp	Ser	His	Phe	Leu	Thr
		115					120						125		
Asp	Ala	Asp	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys
	130					135					140				
Glu	Phe	Phe	His	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu
145					150					155					160
Ser	Lys	Ile	Pro	Glu	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile
				165					170					175	
Tyr	Lys	Asp	Tyr	Val	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Arg	Ile
			180					185					190		
Ser	Val	Tyr	Gln	Val	Leu	Gln	Glu	His	Leu	Ala	Arg	Glu	Ser	Asp	Leu
		195					200					205			
Phe	Leu	Leu	Asp	Ser	Arg	Thr	Leu	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu
	210					215					220				
Val	Phe	Asp	Ile	Thr	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg
225					230					235					240

His	Asn	Leu	Gly	Leu	Gln	Leu	Ser	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser
				245					250					255	
Val	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Thr
			260					265					270		
Lys	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Leu
		275					280					285			
Arg	Ser	Thr	Arg	Ser	Thr	Gly	Gly	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser
	290					295					300				
Lys	Thr	Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Val	Ala	Asn	Val	Ala	Glu
305					310					315					320
Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr
				325					330					335	
Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu
			340					345					350		
Gly	Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn
		355					360					365			
Ser	Tyr	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
	370					375					380				
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
385					390					395					400
Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile
			405						410					415	
Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His	
			420					425					430		

<210> 17

<211> 1296

<212> DNA

<213> Felis catus

<400> 17

atgcacgtgc	gctcgctgcg	cgccgcggcg	ccccacagct	tcgtggcgct	ctgggcgccc	60
ctgttcctgc	tgcgctccgc	cctggccgac	ttcagcctgg	acaacgaggt	gcactcgagc	120
ttcatccacc	ggcgctccg	cagccaggag	cggcgggaga	tgcagcgcgga	gacccctctct	180
atcttgggct	tgccccatcg	cccgcgcccc	cacctccagg	gcaagcaca	ctcggcgccc	240
atgttcatgc	tggacctgta	caacgccatg	gcggtggagg	agggcggcgg	gcccgcgccc	300
cagggcttct	cctaccctta	caaggccgtc	ttcagtaccc	agggcccccc	tctggccagc	360
ctgcaagata	gccgcttcct	caccgacgcc	gacatgggtca	tgagcttcgt	caacctcgtg	420
gagcacgaca	aagagttctt	ccaccacagt	taccaccacc	gggagttccg	gtttgatctt	480
tccaagatcc	cagaagggga	agccgtgacc	gcagccgaat	tccgcatcta	caaggactac	540
atccgggaac	gctttgataa	tgagacgttc	cggatcagcg	tttaccaggt	gcttcaggag	600
cacttgggca	gggagtccga	cctgttcctg	ctggacagcc	gcacgctctg	ggcctcggag	660
gagggctggc	tgggtgttcga	catcacggcc	accagcaacc	actgggtggg	caaccgcg	720
cacaatctgg	gcctgcagct	ctgcgtggag	accttggacg	ggcagagcat	caaccccaag	780
ttggcgggcc	tgatcgggag	gcacggggcc	cagaacaagc	agcccttcat	ggtggccttc	840
ttcaaggcca	cggaggtcca	ccttcgcagc	acccgctcca	cagggggcaa	gcaacgcagc	900
cagaaccgct	ccaagacgcc	caagaaccag	gaagccctgc	gggtgaccaa	cgtcgcagaa	960
aacagcagca	gtgaccagag	gcaggcttgt	aagaagcacg	agctgtacgt	cagcttccgc	1020
gacctgggct	ggcaggactg	gatcatcgct	cccgaaggct	atgctgctta	ctactgcgag	1080
ggggagtgtg	ccttcctctt	gaactcctac	atgaacgcca	ccaaccacgc	catcgtgcag	1140
acgctggtcc	acttcatcaa	cccggagacg	gtgcccgaagc	cgtgctgtgc	ccccacgcag	1200
ctcaacgcca	tctctgtgct	ctacttcgac	gacagctcca	acgtcatcct	gaagaaatac	1260
agaaacatgg	tcgtccgagc	ctgtggctgc	cactag			1296

<210> 18

<211> 1299

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic construct

<400> 18

```

atgcacgtgc gctcactgcg agctgcggcg ccgcacagct tcgtggcgct ctgggcaccc 60
ctgttcctgc tgcgctccgc cctggccgac ttcagcctgg acaacgaggt gcactcgagc 120
ttcatccacc ggcgcctccg cagccaggag cggcgggaga tgcagcgaga gatcctctct 180
atcttgggct tgccccatcg cccgcgcccc cacctccagg gcaagcacia ctcggcgccc 240
atgttcatgc tggacctgta caacgccatg gcggtggagg agggcgggcg gcccgacggc 300
cagggcttct cctaccccta caaggccgtc ttcagtacct agggcccccc tctggccagc 360
ctgcaagata gccgcttcct caccgacgcc gacatgggtca tgagcttcgt caacctcgtg 420
gagcacgaca aagagttctt ccaccacagt taccaccacc gggagttccg gtttgatctt 480
tccaagatcc cagaagggga agccgtgacc gcagccgaat tccgcataca caaggactac 540
atccgggaac gctttgataa tgagacgttc cggatcagcg tttaccagggt gcttcaggag 600
cacttgggca gggagtctga cctgttcctg ctggacagcc gtacgctctg ggcctcggag 660
gagggctggc tgggtgttca catcacggcc accagcaacc actgggtggg caaccgcgg 720
cacaatctgg gcctgcagct ctgcgtggag accttggagc ggcagagcat caacccaag 780
ttggcgggccc tgatcgggag gcacgggccc cagaacaagc agcccttcat ggtggccttc 840
ttcaaggcca cggaggtcca ccttcgcagc acccgctcca cagggggcaa gcaacgcagc 900
cagaaccgct ccaagacgcc caagaaccag gaagccctgc gggtgaccaa cgtcgcagaa 960
aacagcagca gtgaccagag gcaggcttgt aagaagcacg agctgtacgt cagcttccgc 1020
gacctgggct ggcaggactg gatcatcgct cccgaaggct atgctgctta ctactgcgag 1080
ggggagtgtg ccttccctct gaactcctac atgaacgcca ccaaccacgc catcgtgcag 1140
acgctggtcc acttcatcaa cccggagacg gtgcccaagc cgtgctgtgc ccccacgcag 1200
ctcaacgcca tctctgtgct ctacttcgac gacagctcca acgtcatcct gaagaaatac 1260
agaaacatgg tcgtccgagc ctgtggctgc cactagtag 1299

```

<210> 19

<211> 431

<212> PRT

<213> Felis catus

<400> 19

```

Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
1          5          10          15
Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
20          25          30
Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
35          40          45
Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
50          55          60
Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65          70          75          80
Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
85          90          95
Gly Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
100          105          110
Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser Arg Phe Leu Thr
115          120          125
Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
130          135          140
Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
145          150          155          160
Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
165          170          175
Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
180          185          190
Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
195          200          205
Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
210          215          220
Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
225          230          235          240
His Asn Leu Gly Leu Gln Leu Cys Val Glu Thr Leu Asp Gly Gln Ser
245          250          255

```

Ile	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn	
			260					265					270			
Lys	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Leu	
		275					280					285				
Arg	Ser	Thr	Arg	Ser	Thr	Gly	Gly	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser	
	290					295					300					
Lys	Thr	Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Val	Thr	Asn	Val	Ala	Glu	
305					310					315					320	
Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	
			325					330						335		
Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu	
		340						345					350			
Gly	Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn	
	355						360					365				
Ser	Tyr	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His	
	370					375					380					
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln	
385					390					395					400	
Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile	
			405						410					415		
Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His		
		420					425					430				

<210> 20
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 20
 ggatccctag tggcagccac aggctcggac g

31

<210> 21
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 21
 gccaccagca accactgggt ggtc

24

<210> 22
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 22
 ttcagcctgg acaacgaggt gcac

24

<210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 23
 tggttggtgg cgttcatgta 20

<210> 24
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 24
 gggtagcgcg tagagccggc gcg 23

<210> 25
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 25
 cgtcggtgag gaagcggctc ta 22

<210> 26
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 26
 ggatctcgcg ctgcatctcc cg 22

<210> 27
 <211> 1293
 <212> DNA
 <213> Mus musculus

<400> 27
 atgcacgtgc gctcgctgcg cgctgcggcg ccacacagct tcgtggcgct ctggggcgct 60
 ctgttcttgc tgcgctccgc cctggccgat ttcagcctgg acaacgaggt gcactccagc 120
 ttcattccacc ggcgcctccg cagccaggag cggcgggaga tgcagcggga gatcctgtcc 180
 atcttagggg tgcctcatcg cccgcgcccg cacctccagg gaaagcataa ttcggcgccc 240
 atgttcatgt tggacctgta caacgccatg gcggtggagg agagcggggc ggacggacag 300
 ggcttctcct acccctacaa ggccgtcttc agtaccagc gcccccttt agccagcctg 360

```

caggacagcc acttcctcac tgacgccgac atgggtcatga gcttcgtcaa cctagtggaa 420
catgacaaag aattcttcca ccctcgatac caccatcggg agttccggtt tgatctttcc 480
aagatccccg agggcgaagc ggtgaccgca gccgaattca ggatctataa ggactacatc 540
cgggagcgat ttgacaacga gaccttccag atcacagtct atcaggtgct ccaggagcac 600
tcaggcaggg agtcggacct cttcttgctg gacagccgca ccattctgggc ttctgaggag 660
ggctgggttg tgtttgatat cacagccacc agcaaccact ggggtggtcaa ccctcggcac 720
aacctgggct tacagctctc tgtggagacc ctggatgggc agagcatcaa cccaagttg 780
gcaggcctga ttggacggca tggaccccag aacaagcaac ctttcatggt ggccttcttc 840
aaggccacgg aagtccatct ccgtagtatc cgggtccacgg ggggcaagca gcgcagccag 900
aatcgctcca agacgcaaaa gaaccaagag gccctgagga tggccagtgt ggcagaaaac 960
agcagcagtg accagaggca ggcctgcaag aaacatgagc tgtacgtcag cttccgagac 1020
cttggctggc aggactggat cattgcacct gaaggctatg ctgcctacta ctgtgaggga 1080
gagtgcgct tccctctgaa ctctacatg aacgccacca accacgccat cgtccagaca 1140
ctggttcact tcatcaaccc agacacagta cccaagccct gctgtgcgcc caccagctc 1200
aacgccatct ctgtcctcta cttcgacgac agctctaata tcattcctgaa gaagtacaga 1260
aacatgggtg tccgggcctg tggctgccac tag 1293

```

<210> 28

<211> 430

<212> PRT

<213> Mus musculus

<400> 28

```

Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
1          5          10          15
Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
          20          25          30
Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
          35          40          45
Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
          50          55          60
Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65          70          75          80
Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly
          85          90          95
Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr
          100          105          110
Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp
          115          120          125
Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu
          130          135          140
Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser
145          150          155          160
Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr
          165          170          175
Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr
          180          185          190
Val Tyr Gln Val Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe
          195          200          205
Leu Leu Asp Ser Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val
          210          215          220
Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His
225          230          235          240
Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile
          245          250          255
Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys
          260          265          270
Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg
          275          280          285
Ser Ile Arg Ser Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys
          290          295          300
Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn
305          310          315          320

```

Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val
 325 330 335
 Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly
 340 345 350
 Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser
 355 360 365
 Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe
 370 375 380
 Ile Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu
 385 390 395 400
 Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu
 405 410 415
 Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
 420 425 430

<210> 29
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 29
 tcagtcatag ccatacgacag a

21

<210> 30
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 30
 gtgctggctg gcacgggcat t

21

<210> 31
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 31
 atgtccacca aagtcccctc t

21

<210> 32
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 32
cccggggcgt cgtatggata t 21

<210> 33
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 33
gatacgcgtt ccattagcag atct 24

<210> 34
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 34
ggacaccttt ctgatacgtt catt 24

<210> 35
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 35
gatacgcgtt ccattagcag atctttgagg ggcttgaaa taggc 45

<210> 36
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 36
ggttgtgtgg aagaccggg ggcg 24

<210> 37
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 37
agatctgcta atggaacgcg tatcgctgcc cccacagtac agcaa 45

<210> 38
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 38
ctagtcattct taacgcgtgt cctcaacatc acccgaga 38

<210> 39
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 39
cttgcttggt attaaaaaaaa g 21

<210> 40
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 40
atcttaacgc gtcctcagc cttctaattg gac 33

<210> 41
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 41
atcgtaaagc ttaatgtcgt aataaccccc c 31

<210> 42
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 42
tctactgcag ccggtgtctt ctatggaggt ca 32

<210> 43
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 43
tcttcgcccc cgttttcacc atgg 24

<210> 44
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 44
atcacgccgc ggcttaaaaa aattacgccc cgcc 34

<210> 45
<211> 71
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 45
aattcggtac caagcttctt tattctatac ttaaaaagtg aaaataaata caaagggttct 60
tgactctctt c 71

<210> 46
<211> 70
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 46
cgcacgcgtg tctgcgaggg ccagctggtg ggctcgcggt tgaggacaaa ctcttcgcgg 60
tctttccagt 70

<210> 47
<211> 70
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 47

actcttggat cggaaacccg tcggcctccg aacgtactcc gccaccgagg gacctgagcg 60
agtccgcatc 70

<210> 48

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 48

gaccg gatcg gaaaacctct cgagaaaggc gtctaaccag tcacagtcgc aagcccgggt 60

<210> 49

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 49

ctttgtatatt attttcactt tttaagtata gaataaagaa gcttggtacc g 51

<210> 50

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 50

gaagagtttg tcctcaaccg cgagcccaac agctggccct cgcagacagc gatgcggaag 60
agagtcaaga ac 72

<210> 51

<211> 73

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 51

gctcaggtcc ctcggtggcg gagtacgttc ggaggccgac gggtttccga tccaagagta 60
ctggaaagac cgc 73

<210> 52
 <211> 75
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 52
 ctagacccgg gcttgcgact gtgactgggt agacgccttt ctgagaggt tttccgatcc 60
 ggatgatgac gactc 75

<210> 53
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 53
 atcgctctgc agactctctt ccgcatcgct gtctgc 36

<210> 54
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 54
 gctctagact tgcgactgtg actgggttag 29

<210> 55
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 55
 cgttttagtga accgtctgca 20

<210> 56
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 56
 gacggttcac taaacgagct 20

<210> 57
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 primer

<400> 57

gtaaaaacga cggccagt

18

<210> 58
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 primer

<400> 58

atcgtcccgc ggaattgttg ttgttaactt gtt

33

<210> 59
 <211> 537
 <212> DNA
 <213> Equus caballus

<400> 59

atgcacagct	cagcactgct	atgttacctg	gtcttcctgg	ccgggggtggg	agccagccga	60
gaccggggca	cccagtctga	gaacagctgc	accacttcc	caaccagcct	gccccacatg	120
ctccatgagc	tccgagccgc	cttcagcagg	gtgaagactt	tctttcaaat	gaaggaccag	180
ctggacaaca	tggtgttgaa	cgggtccctg	ctggaggact	ttaagggtta	cctgggttgc	240
caagccttgt	cggagatgat	ccagttttac	ctggaggagg	tgatgccccca	ggctgagAAC	300
cacggcccag	acatcaagga	gcacgtgaac	tccctggggg	aaaagctgaa	gaccctccga	360
gtgaggctgc	ggcgctgtca	tcgatttctg	ccctgtgaaa	ataagagcaa	ggcagtggag	420
caggtgaaga	gtgccttcag	taagctccaa	gagaaagggtg	tctacaaagc	catgagtga	480
tttgacatct	tcataacta	catagaagcc	tatatgacaa	cgaagatgaa	aaactga	537

<210> 60
 <211> 178
 <212> PRT
 <213> Equus caballus

<400> 60

Met	His	Ser	Ser	Ala	Leu	Leu	Cys	Tyr	Leu	Val	Phe	Leu	Ala	Gly	Val
1				5					10					15	
Gly	Ala	Ser	Arg	Asp	Arg	Gly	Thr	Gln	Ser	Glu	Asn	Ser	Cys	Thr	His
			20					25					30		
Phe	Pro	Thr	Ser	Leu	Pro	His	Met	Leu	His	Glu	Leu	Arg	Ala	Ala	Phe
		35					40					45			
Ser	Arg	Val	Lys	Thr	Phe	Phe	Gln	Met	Lys	Asp	Gln	Leu	Asp	Asn	Met
	50					55				60					
Leu	Leu	Asn	Gly	Ser	Leu	Leu	Glu	Asp	Phe	Lys	Gly	Tyr	Leu	Gly	Cys
65					70					75				80	
Gln	Ala	Leu	Ser	Glu	Met	Ile	Gln	Phe	Tyr	Leu	Glu	Glu	Val	Met	Pro
			85					90					95		
Gln	Ala	Glu	Asn	His	Gly	Pro	Asp	Ile	Lys	Glu	His	Val	Asn	Ser	Leu
			100					105					110		

Gly Glu Lys Leu Lys Thr Leu Arg Val Arg Leu Arg Arg Cys His Arg
 115 120 125
 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Ser
 130 135 140
 Ala Phe Ser Lys Leu Gln Glu Lys Gly Val Tyr Lys Ala Met Ser Glu
 145 150 155 160
 Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Thr Lys Met
 165 170 175
 Lys Asn

<210> 61
 <211> 540
 <212> DNA
 <213> Canis lupus

<400> 61
 atgccagcc cagcactgct ctgttgctgc ctggtcctcc tggccggggt gggagccagc 60
 cgacaccaga gcaccctacc tgaggacgac tgcaccact tcccagccag cctgccccac 120
 atgctccgag agctccgagc tgccttcggg aggggtgaaga ctttctttca aatgaaggac 180
 aagctggaca acatactgct gaccgggtcc ctgctggagg actttaagag ttacctgggt 240
 tgccaagccc tgctggagat gatccagttt tacttggagg aggtgatgcc ccgggctgag 300
 aaccacgacc cagacatcaa gaaccacgtg aactccctgg gagagaagct caagaccctc 360
 aggctgaggg tgcgacgctg tcaccgattt ctgccctgtg agaataagag caaggcgggtg 420
 gagcaggtga agagcgcatc tagtaagctc caggagaaaag gtgtctacaa agccatgagt 480
 gagtttgaca tcttcatcaa ctacatagaa acctacatga caatgaggat gaaaatctga 540

<210> 62
 <211> 179
 <212> PRT
 <213> Canis lupus

<400> 62
 Met Pro Ser Pro Ala Leu Leu Cys Cys Cys Leu Val Leu Leu Ala Gly
 1 5 10 15
 Val Gly Ala Ser Arg His Gln Ser Thr Leu Pro Glu Asp Asp Cys Thr
 20 25 30
 His Phe Pro Ala Ser Leu Pro His Met Leu Arg Glu Leu Arg Ala Ala
 35 40 45
 Phe Gly Arg Val Lys Thr Phe Phe Gln Met Lys Asp Lys Leu Asp Asn
 50 55 60
 Ile Leu Leu Thr Gly Ser Leu Leu Glu Asp Phe Lys Ser Tyr Leu Gly
 65 70 75 80
 Cys Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met
 85 90 95
 Pro Arg Ala Glu Asn His Asp Pro Asp Ile Lys Asn His Val Asn Ser
 100 105 110
 Leu Gly Glu Lys Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His
 115 120 125
 Arg Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys
 130 135 140
 Ser Ala Phe Ser Lys Leu Gln Glu Lys Gly Val Tyr Lys Ala Met Ser
 145 150 155 160
 Glu Phe Asp Ile Phe Ile Asn Tyr Ile Glu Thr Tyr Met Thr Met Arg
 165 170 175
 Met Lys Ile

<210> 63
 <211> 537
 <212> DNA
 <213> Felis catus

<400> 63

```

atgcacagct cagcacttct gtgtttcctg gtcttcctgg ccggggtagg agccagccga      60
caccagagca ccctgtctga ggacaactgc acccacttct cagtcagcct gccccacatg      120
ctccragagc tccgagctgc cttcggcaag gtgaagactt tctttcaaac caaggacgag      180
ctgcacagca tattgttgac caggtccttg ctggaggact ttaagggtta cctggggttg      240
caagccttgt ccgagatgat ccagttttat ttggaggagg tgatgccccca ggctgagaac      300
gaggacccag acatcaaaca gcacgtgaac tccctggggag aaaagctgaa gaccctccgg      360
ctgagactgc ggcgctgtca tcgatttctg ccctgtgaaa acaagagcaa ggtggtggag      420
caggtgaaga gtacctttag taagctccaa gagaaagggt tctacaaagc catgggtgag      480
tttgacatct tcatcaacta catagaagct tacatgacaa tgaagatgaa aatctga      537

```

<210> 64

<211> 178

<212> PRT

<213> Felis catus

<220>

<221> MOD_RES

<222> (42)..(42)

<223> Variable amino acid

<400> 64

```

Met His Ser Ser Ala Leu Leu Cys Phe Leu Val Phe Leu Ala Gly Val
1          5          10          15
Gly Ala Ser Arg His Gln Ser Thr Leu Ser Glu Asp Asn Cys Thr His
          20          25          30
Phe Ser Val Ser Leu Pro His Met Leu Xaa Glu Leu Arg Ala Ala Phe
          35          40          45
Gly Lys Val Lys Thr Phe Phe Gln Thr Lys Asp Glu Leu His Ser Ile
          50          55          60
Leu Leu Thr Arg Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys
65          70          75          80
Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro
          85          90          95
Gln Ala Glu Asn Glu Asp Pro Asp Ile Lys Gln His Val Asn Ser Leu
          100          105          110
Gly Glu Lys Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg
          115          120          125
Phe Leu Pro Cys Glu Asn Lys Ser Lys Val Val Glu Gln Val Lys Ser
          130          135          140
Thr Phe Ser Lys Leu Gln Glu Lys Gly Val Tyr Lys Ala Met Gly Glu
145          150          155          160
Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Met
          165          170          175
Lys Ile

```

<210> 65

<211> 537

<212> DNA

<213> Homo sapiens

<400> 65

```

atgcacagct cagcactgct ctgttgccctg gtcctcctga ctgggggtgag ggccagccca      60
ggccagggca cccagtctga gaacagctgc acccacttcc caggcaacct gcctaacatg      120
cttcgagatc tccgagatgc cttcagcaga gtgaagactt tctttcaaata gaaggatcag      180
ctggacaact tgttgttaaaa ggagtccttg ctggaggact ttaagggtta cctggggttg      240
caagccttgt ctgagatgat ccagttttac ctggaggagg tgatgccccca agctgagaac      300
caagacccag acatcaaggc gcatgtgaac tccctggggg agaacctgaa gaccctcagg      360
ctgaggctac ggcgctgtca tcgatttctt ccctgtgaaa acaagagcaa ggccgtggag      420
caggtgaaga atgcctttaa taagctccaa gagaaaggca tctacaaagc catgagttag      480
tttgacatct tcatcaacta catagaagcc tacatgacaa tgaagatacg aaactga      537

```

<210> 66
 <211> 178
 <212> PRT
 <213> Homo sapiens

<400> 66
 Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val
 1 5 10 15
 Arg Ala Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His
 20 25 30
 Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe
 35 40 45
 Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu
 50 55 60
 Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys
 65 70 75 80
 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro
 85 90 95
 Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu
 100 105 110
 Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg
 115 120 125
 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn
 130 135 140
 Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu
 145 150 155 160
 Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile
 165 170 175
 Arg Asn

<210> 67
 <211> 528
 <212> DNA
 <213> Human herpesvirus 5

<400> 67
 atgctgtcgg tgatggtctc ttcctctctg gtcctgatcg tcttttttct aggcgcttcc 60
 gaggaggcga agccggcgac gacgacgata aagaatacaa agccgcagtg tcgtccagag 120
 gattacgcga ccagattgca agatctccgc gtcacctttc atcgagtaaa acctacgttg 180
 caacgtgagg acgactactc cgtgtgggctc gacgggtacgg tgggtcaaagg ctggttgggga 240
 tgcagcgtca tggactgggt gttgaggcgg tatctggaga tcgtgtttcc cgcaggcgac 300
 cacgtctatc ccggactcaa gacggaattg catagtatgc gctcgacgct agaatccatc 360
 taaaagaca tgcggcaatg tcctctgtta gggtgcggag ataagtccgt gattagtcgg 420
 ctgtctcagg aggcggaaag gaaatcggat aacggcacgc ggaaaggtct cagcgagttg 480
 gacacgttgt ttagccgtct cgaagagtat ctgcactcga gaaagtag 528

<210> 68
 <211> 175
 <212> PRT
 <213> Human herpesvirus 5

<400> 68
 Met Leu Ser Val Met Val Ser Ser Ser Leu Val Leu Ile Val Phe Phe
 1 5 10 15
 Leu Gly Ala Ser Glu Glu Ala Lys Pro Ala Thr Thr Thr Ile Lys Asn
 20 25 30
 Thr Lys Pro Gln Cys Arg Pro Glu Asp Tyr Ala Thr Arg Leu Gln Asp
 35 40 45
 Leu Arg Val Thr Phe His Arg Val Lys Pro Thr Leu Gln Arg Glu Asp
 50 55 60
 Asp Tyr Ser Val Trp Leu Asp Gly Thr Val Val Lys Gly Cys Trp Gly
 65 70 75 80

Cys	Ser	Val	Met	Asp	Trp	Leu	Leu	Arg	Arg	Tyr	Leu	Glu	Ile	Val	Phe	
				85					90					95		
Pro	Ala	Gly	Asp	His	Val	Tyr	Pro	Gly	Leu	Lys	Thr	Glu	Leu	His	Ser	
			100					105					110			
Met	Arg	Ser	Thr	Leu	Glu	Ser	Ile	Tyr	Lys	Asp	Met	Arg	Gln	Cys	Pro	
		115					120					125				
Leu	Leu	Gly	Cys	Gly	Asp	Lys	Ser	Val	Ile	Ser	Arg	Leu	Ser	Gln	Glu	
	130					135					140					
Ala	Glu	Arg	Lys	Ser	Asp	Asn	Gly	Thr	Arg	Lys	Gly	Leu	Ser	Glu	Leu	
145					150					155					160	
Asp	Thr	Leu	Phe	Ser	Arg	Leu	Glu	Glu	Tyr	Leu	His	Ser	Arg	Lys		
			165						170					175		

51440-134

CLAIMS:

1. Use of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle and recombinant adenovirus vectors containing a nucleic acid sequence encoding a BMP-7 polypeptide operatively linked to a promoter for
5 treating a non-human mammalian subject suffering from osteoarthritis, wherein the composition is for intra-articular administration to said non-human mammalian subject, wherein the BMP-7 polypeptide is expressed in vivo in the non-human mammalian subject, and wherein the BMP-7 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, and
10 SEQ ID NO:28.
2. The use according to claim 1, wherein the nucleic acid sequence encoding the BMP-7 polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 27.
- 15 3. The use according to claim 1 or 2, wherein the recombinant adenovirus vectors are human adenoviruses.
4. The use according to claim 3, wherein the human adenoviruses are human adenoviruses type 5 (hAd5).
5. The use according to claim 4, wherein the human adenoviruses type 5 (hAd5)
20 are PEGylated.
6. The use according to claim 1 or 2, wherein the recombinant adenovirus vectors are canine adenoviruses.
7. The use according to claim 6, wherein the canine adenoviruses are canine adenoviruses type 2 (CAV2).
- 25 8. The use according to any one of claims 1 to 7, wherein the non-human mammalian subject is selected from the group consisting of canidae, equidae and felidae.

51440-134

9. The use according to any one of claims 1 to 7, wherein the non-human mammalian subject is a dog, a bitch or a puppy.
10. The use according to any one of claims 1 to 7, wherein the non-human mammalian subject is a cat or a kitten.
- 5 11. The use according to any one of claims 1 to 7, wherein the non-human mammalian subject is a horse, a mare or a foal.
12. The use according to any one of claims 1 to 11, wherein the BMP-7 polypeptide is linked to a signal peptide.
13. The use according to claim 12, wherein the signal peptide is selected from the

10 group consisting of the BMP-7 signal sequence, the IGF-1 signal sequence, and the tPA signal sequence.
14. The use according to claim 12, wherein the signal peptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 11.
- 15 15. The use according to claim 12, wherein the signal peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 12.
16. The use according to any one of claims 1 to 15, wherein the promoter is selected from the group consisting of a CMV IE promoter, a RSV promoter, an HSV-1 TK

20 promoter, a SV40 early promoter, a SV40 late promoter, an adenovirus major late promoter, a phosphoglycerate kinase gene promoter, a metallothionein gene promoter, an α -1 antitrypsin gene promoter, an albumin gene promoter, a collagenase gene promoter, an elastase I gene promoter, a β -actin gene promoter, a β -globin gene promoter, a γ -globin gene promoter, an α -fetoprotein gene promoter, and a muscle creatin kinase gene promoter.

Figure 1


Animal #	Treatment	Location and Macroscopic Lesions			Comments
		Medial Femoral Condyle	Tibial Plateau	Patella	
1L	Ad5 BMP-7	sm, ptd fers	nsf	nsf	Clear improvement L>R
1R	Control	lg ftd, wl, C, mndeg	lat wl	med ftd	
5L	Control	ftd, ptd + fers, thin	lg ost, pt fers	nsf	Clear improvement R>L
5R	Ad5 BMP-7	sm area ptd + fers, focal repair tissue	sm, fers	nsf	
9L	Ad5 BMP-7	focal sm thin or fers	mild fers		Clear improvement L>R
9R	Control	sm ftd + lg fers rt, dp, possible mndeg	pt fers thin	nsf	
13L	Control	sm area ftd + fers, wr	fers	nsf	R has less complete loss of cartilage at injury site than L
13R	Ad5 BMP-7	sm area ptd with fers	fers	nsf	
17L	Ad5 BMP-7	sm area fers, limited extension	nsf	nsf	L reduction in size & depth compared to R
17R	Control	larger area fers ptd + ftd, expansion clear	nsf	nsf	
30L	Control	ftd and ptd, fers moderate radiation from injury	medial thin	fers	R clear reduction in size and depth compared to L
20R	Ad5 BMP-7	focal contained small ptd + limited fcr	nearly normal	nearly normal	
23L	Ad5 BMP-7	extension ftd from injry site, ptd fers	nsf	nsf	roughly equivalent though L tibia better than R
23R	Control	extension of ftd from injury site, ptd + fers	medial thin	fers	
26L	Control	euthanized during experiment due to septicemia and pneumonia			
26R	Ad5 BMP-7				

FTD	full thickness defect
PTD	Partial thickness defect
WL	Wear lines
Fsr	fissures
Ost	osteophyte
lg	large
sm	small
med	medial
lat	lateral
mndeg	meniscal degeneration, fibre separation
thin	cartilage thinning
nsf	no significant findings
rt	repair tissue
dp	depressed area

2/4

Figure 2

Y13 Contralateral control



Y13 Treated joint




Figure 3




Figure 4

